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In the months since our last 
issue of Yale Medicine appeared, 
we’ve seen a visit from our 
nation’s Surgeon General (who 
also happens to be a recent 
alumnus); teenagers with diabe-
tes climbing rock walls thanks 
to an artificial pancreas devel-
oped by School of Medicine fac-
ulty; hackathons that seek novel 
solutions to health care prob-
lems; and a new joint M.D./Ph.D. 
program with the University of 
Puerto Rico.
Exciting news also comes 
from beyond the corner of 
Cedar Street and Congress 
Avenue. A member of the Class 
of 2004 has been working 
with indigenous people in the 
Amazon rainforest to compile 
an encyclopedia of medici-
nal plants used by shamans. 
Another alumnus from the Class 
of 1949, still active at the age 
of 93, is seeking ways to help 
doctors in training cope with 
the personal and professional 
stressors of a life in medicine. 
A member of the Class of 1990 
has taken a contrarian view 
of e-cigarettes—despite their 
dangers, he believes, they can 
still help people quit smoking. 
On a lighter note, a lunchtime 
painting class offers partici-
pants a brief respite from the 
office, lab, or clinic.
Chronicles of all these 
activities and more are inside 
the pages of our Winter issue 
of Yale Medicine. As ever, we 
strive to let you know not only 
what’s happening on the medi-
cal school campus, but also 
what our alumni, faculty, and 
students are accomplishing in 
New Haven and the world. And 
because there’s always more 
news than we can fit inside 
the pages of the magazine, we 
encourage you to visit us online 
for more events and discoveries 
from the School of Medicine.
 John Curtis 
Editor, Yale Medicine
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  The machinery of medicine:  
how technology influences  
 medical research and clinical care
S I NC E N E OL I T H IC H U M A N S fashioned the first scalpel out of stone, 
new machines and methods have changed the way we practice 
medicine and learn about the human body. Physicians moved on 
from those early scalpels to stethoscopes, X-rays, and MRIs, the 
better to understand the workings of the human body. With these 
new understandings has come translational research that trans-
fers findings from the lab into new, more effective treatments 
and medicines. Dean Robert J. Alpern, M.D., Ensign Professor of 
Medicine, discussed basic science and advances in clinical care; 
technology and patient care; and the role of serendipity in research 
with Yale Medicine.
What have been some of the key inventions or discoveries that have advanced 
clinical care and medical research? In the past 50 to 100 years, there have been 
so many advances that it’s hard to rank any one above the other. Obviously, 
some come to mind—the discovery of the structure of DNA, recombinant DNA, 
electron microscopy, knockout technology. The new gene editing technology, 
CRISPR, is really going to transform research. It’s important to point out that 
the major advances in health care have been based on basic scientific findings. 
DNA technology and the structure of DNA were basic science findings that now 
drive clinical genetics. The understanding of how cells grow has transformed 
cancer care. Basic understandings of the immune system have led to immuno-
therapy for cancer.
How do physicians integrate new technologies into medicine while maintaining 
the doctor-patient relationship? Technology is always good for improving what 
physicians can do, but you run the risk that doctors won’t hone their clinical 
skills as well as they could because they know that the technology will end up 
defining the diagnosis. There needs to be a combination of the two. I don’t see 
technology replacing the need for outstanding clinicians. Technology should 
enhance clinical skills, not replace them.
How important is serendipity in scientific discovery? There are stories of serendip-
ity, but the best investigators always appear to have good luck. The best inves-
tigators are asking the right questions, the important questions. It’s a matter of 
staying knowledgeable about all of the technologies, including those from other 
fields, and thinking about how to apply them to your field. When you ask the 
right question and use the right technology, serendipity falls upon you. 
dialogue
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W H E N V I V E K H. M U RT H Y, M.D. ’03,  M.B.A . ’03, returned 
to Yale in September, it was his first visit to his alma mater 
in the navy blue uniform of the U.S. Surgeon General. As he 
walked through the campus during his two days at Yale, he 
encountered constant reminders of the five years he spent 
in New Haven as a student—the shade tree on Hillhouse 
Avenue where he studied and wrote in his journal; the lec-
ture hall where a classmate was so intent on taking notes 
that he never noticed when the professor called on him; and 
the former teachers who are now his colleagues.
  Our collective will, says  
the Surgeon General, can give  
 “every man, woman, and child  
  a fair shot at good health”
»
After his talk in Harkness 
Auditorium, Surgeon 
General Vivek Murthy 
posed for a selfie with 
Neil Pathak, a first-year 
medical student, and 
Rachel Solnick, a resident 
in emergency medicine.
During a talk in Harkness 
Auditorium, one of four he gave 
in New Haven, Murthy fielded a 
question from Cary Gross, M.D., 
professor of medicine, who said, 
“Welcome back. You’ve made us 
all proud.”
Murthy turned to the audi-
ence and said, “Dr. Cary Gross 
was, in fact, my thesis advisor.” 
And to Gross, “I just had a flash-
back to sitting in your office.”
The exchange was a reminder 
that Murthy is just 12 years out 
of med school and one of the 
youngest surgeons general in 
recent history. And that his ties 
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to the School of Medicine are 
both recent and strong. “It really 
feels like coming home,” he  
said. “I spent five years here, 
exploring new ideas, meeting 
new people.”
He came at the invitation of 
Howard P. Forman, M.D., M.B.A., 
a mentor since Murthy’s student 
days. “He agreed immediately,” 
said Forman, professor of radi-
ology and medical imaging, of 
chronicle
economics, of management, and 
of public health, and director of 
the M.D./M.B.A. Program. “It was 
just a matter of finding the time.”
In Murthy’s talks at Yale and at 
Gateway Community College, he 
advanced his vision of a healthy 
nation—one that relies on part-
nerships and collaborations that 
may seem like strange bedfellows. 
Take shopping malls. For many of 
us, they symbolize consumerism 
and crass consumption. Others 
see them as a convenient place to 
shop or hang out, a place where 
you can buy everything from 
handbags to sleeping bags, enjoy a 
meal, and take in a movie.
Murthy sees a partner.
Such a seemingly offbeat col-
laboration is central to Murthy’s 
vision of a healthy America, one 
that he outlined in his multiple 
appearances in September. He 
stopped first at the School of 
Epidemiology and Public Health 
on September 16, followed by a 
talk that afternoon at the School 
of Management. The next day he 
joined a panel (which included 
city and state health officials) 
at Gateway Community College 
to discuss antismoking efforts. 
That afternoon he spoke at the 
School of Medicine in the same 
Harkness Auditorium where, as 
Forman noted, he’d donned his 
first white coat.
It was at the School of 
Management that Murthy dis-
cussed the partnership he’s seek-
ing with owners and operators of 
shopping malls. His vision starts 
with his belief that all things in 
life—from taking a walk in your 
neighborhood to nurturing your 
dreams and passions—stem from 
good health. “Health is the com-
mon thread that weaves through 
everything that we do,” he said. 
“If we don’t have health, we don’t 
have anything else.”
If all things flow from health, 
then it behooves all of society—
not just doctors and nurses and 
public health experts—to take 
an active role in keeping people 
healthy. All of us have a part to 
play, whether we know it or not. 
Murthy recognizes that health 
is a complex issue that must 
take into account more than 
blood pressure readings and our 
body mass index. Good health 
also means access to healthful 
food, the ability to exercise, and 
freedom from poverty—in other 
words, addressing the inequities 
and disparities in our society. 
But Murthy remains undaunted. 
“We are used to thinking that 
complex problems require com-
plex solutions,” he said. “That  
is not always the case.”
In all his presentations, he 
broke down large problems into 
manageable pieces and suggested 
solutions that usually involve 
some sort of collaboration. As 
Surgeon General, Murthy seeks 
to harness the power of eclectic 
partnerships among apparently 
disparate sectors of society—like 
the Indiana community in which 
police, educators, and public 
health leaders work together 
to tackle an epidemic of opiate 
abuse. “We can’t prosecute our 
way out of the problem,” Murthy 
said of drug abuse. “It is not a 
moral failing. It is something 
that requires treatment.” Other 
examples of the times when  
“we get it right” include a pro-
gram in Virginia that introduces 
students to fresh vegetables,  
and another that doubles the 
value of food stamps at farmers’ 
markets, making fresh produce 
more accessible. 
One of Murthy’s favorite 
solutions is walking, part of 
“restoring a culture of physi-
cal activity.” Just 22 minutes of 
walking a day, he said, greatly 
reduces the risk of heart disease 
or diabetes.
“Walking is one of the most 
powerful things we can do as a 
society to roll back the wave of 
chronic disease we are facing,” 
he said. That’s why he’s been 
partnering with mall owners to 
implement walking programs. 
“When it’s incredibly hot or 
incredibly cold, where better  
to walk than in a mall? You can 
do it with other people. It’s a 
social event.” 
A healthy society, he believes, 
can be achieved through “col-
lective will,” the force that led 
a band of colonists to take on 
the British Empire; a nation to 
take on racial discrimination; 
and medicine and science to 
take on the HIV epidemic. With 
collective will, he said, we can 
improve health for all. At the 
medical school, he called on the 
future physicians to join him by 
seeing themselves in a new role 
as leaders in their communities 
who bring together resources 















Med students add 
Medical French to their 
arsenal of skills.
Medicine in the wild: 
students learn how to 
treat ailments in the 
outdoors.
Full stories and event 
photo galleries, as well 
as other online-only 
content, can be found 
on our home page at 
yalemedicine.yale.edu.
photographs, and illustrations. 
Filled with pride and optimism 
in the wake of the project, sev-
eral young Matsés have now 
stepped up to apprentice to sha-
mans, Herndon reported.
“With the medicinal plant 
knowledge disappearing fast 
among most indigenous groups 
and no one to write it down, the 
true losers in the end are tragi-
cally the indigenous stake-
holders themselves,” Herndon 
said. “Th e methodology devel-
oped by the Matsés and Acaté 
can be a template for other 
indigenous cultures to safeguard 
their ancestral knowledge.”
Th at methodology was 
entirely homegrown. To com-
pile the encyclopedia, fi ve 
elderly shamans paired off with 
younger tribe members literate 
in the Matsés language. Over 
two years, the elders divulged 
all they knew about pharmaceu-
tical organisms, diagnoses, and 
treatments, while the youths 
took notes and photographs. 
being individual providers of 
care to being leaders who can 
communicate and convene—that 
is a cultural shift, an important 
one, and one that I’m hopeful 
we can achieve,” he said.
“What kind of country do 
we want to build with our col-
lective will?” he continued. 
“I see a country where every 
man, woman, and child has a 
fair shot at good health. Never, 
ever believe that this challenge 
is bigger than our collective will. 







When a member of the Amazon 
Matsés tribe develops the tell-
tale sore of the parasitic disease 
leishmaniasis, the tribal shaman 
knows what to prescribe: heated 
scrapings from the outer bark of 
a particular vine. For untold gen-
erations, this indigenous group 
on the Peru-Brazil border has 
counted on the forest’s vast array 
of medicinal plants and animals 
to treat its maladies and enhance 
survival practices like hunting.
But the tribe’s self-suffi  cient 
healing tradition and the for-
est it depends on are under 
threat. Recent sustained con-
tact with the outside world has 
rapidly led to cultural erosion, 
discrimination, and resource 
grabs by outsiders, hurting the 
tribe’s self-suffi  ciency and its 
relationship to the land. Worse, 
the elderly shamans who know 
the rainforest’s secrets are 
dying, and their knowledge is 
becoming lost even as the tribe 
depends on them for health 
care. And because of shame 
learned from missionaries who 
viewed traditional healing as 
“witchcraft,” until recently no 
younger Matsés were training to 
become shamans.
 Th ey are now. Th anks in 
part to Acaté Amazon Conser-
vation, a nonprofi t co-founded 
by Christopher N. Herndon, 
M.D. ’04, the tribe has captured 
and preserved its elders’ knowl-
edge and inspired its youth by 
writing an encyclopedia, one 
intended for use in training the 
next generation of tribal heal-
ers. Th e encyclopedia—which 
Herndon believes is the fi rst 
ethnobotanical inventory of 
an Amazonian tribe to be writ-
ten by the indigenous people 
themselves—describes hundreds 
of plants in 500 pages of text, 
Herndon played a role in 
producing an encyclo-
pedia of such plants, 
and Esitrón is the village 
where an apprentice 
program was piloted to 
pass on this knowledge.
Christopher Herndon 
learns about medicinal 
plants on a rainforest 
trail from Cesar Necqua, 
a shaman from the 
Matsés village of Esitrón 
in the Peruvian Amazon. 
chronicle
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 Herndon met the Matsés in 
2011 after completing his fellow-
ship in reproductive endocrinol-
ogy at the University of California, 
San Francisco. In 2012 he co-
founded Acaté with William Park, 
an agroforester who helps the 
formerly seminomadic Matsés 
develop sustainable farming 
techniques to adapt to their now-
more-permanent settlements.
 Their health system too  
may soon become more sustain-
able. One of the young shamanic 
apprentices is also the local  
government health promoter,  
a vanguard of the Matsés’  
next plan: to develop an inte-
grated Western and tribal  
health system that offers the 
best of both worlds.
—Jenny Blair
»
Yale and University of 
Puerto Rico collaborate  
on M.D./Ph.D. studies
When Daniel A. Colón-Ramos, 
Ph.D., arrived from Puerto Rico 
to begin his Harvard under-
graduate career in 1994, things 
didn’t exactly go as planned. 
Moving to the campus early for 
a summer program, he took a 
taxi from Logan Airport into 
Cambridge. But once in his 
dorm room, he set down his 
bags and lay on the bed feel-
ing dizzy—and by the time 
his roommate arrived, Colón-
Ramos recalled, “I told him, 
‘I’m dying. You have to take  
me to the hospital.’ ”
now sold on the Internet by non-
Matsés. Herndon said he can’t 
disclose Matsés remedies due to 
Acaté’s agreement with the tribe.
 Ethnobiology and ethno-
medicine have long emphasized 
the importance of cataloging 
traditional plant uses, said Yale 
anthropology professor Claudia 
Valeggia, Ph.D., who studies the 
health of Latin American indig-
enous groups. What makes the 
encyclopedia unique, she said, is 
that its monolingual nature will 
keep it within the community. 
“This is an invaluable survival 
kit, not only literally—it can save 
lives and alleviate a lot of suf-
fering—but also metaphorically 
as an important aspect of the 
Matsés culture.”
 Herndon, a reproductive 
endocrinologist in Berkeley, Calif., 
has worked with indigenous 
South American tribes since he 
was in medical school, initially 
through a Downs Fellowship 
in the summer of his first year 
at Yale. For his medical student 
thesis, which was awarded the 
Ferris Prize on his graduation in 
2004, he studied the Tiriyó people 
of Suriname, a small country on 
the northeastern coast of South 
America, and wrote about their 
knowledge of anatomy and dis-
ease as well as plants. This knowl-
edge remains vitally important. 
Though Western medicine can  
be helpful in the Amazon, remote 
health stations are often under-
stocked, personnel poorly trained, 
and treatment options expensive, 
impractical, or able to cause  
dangerous side effects.
Last May, tribe members met to 
compile the information into a 
single document. Though Acaté 
provided support, including a 
laptop and help with formatting, 
the project was entirely led and 
undertaken by the Matsés.
Significantly, the tome is in 
the Matsés language—whose 
written version was developed 
by missionaries in order to 
translate the Bible—but it won’t 
be translated.
 That’s a measure to pro-
tect this traditional body of 
knowledge from commercial 
exploitation, a practice some call 
biopiracy and one the Matsés are 
all too familiar with. The rain-
forest’s pharmaceutical gifts are 
legion, including the antima-
larial drug quinine, the muscle 
relaxant curare, and the stimu-
lant cocaine, among others.  
Westerners eager to explore 
them further don’t always take 
tribal interests into account. In 
the early 2000s, without per-
mission from or sharing with 
the tribe, a Seattle company and 
others patented versions of sev-
eral peptides from the Acaté frog 
(Phyllomedusa bicolor)—whose 
skin secretions the Matsés use 
to alter consciousness, heighten 
senses, and confer feelings of 
strength and courage—for use as 
painkillers. Another substance 
in the public domain used by the 
Matsés and neighboring tribes 
is bëcchëte, a type of milkwood 
whose secretions applied to  
the eyes are reported to help 
hunters better distinguish tex-















No one could fi gure out 
what was wrong. Th e hospital 
physicians suspected menin-
gitis, but results of a spinal tap 
were negative. Eventually, said 
Colón-Ramos, now an associ-
ate professor of cell biology and 
neuroscience at the School of 
Medicine, they tracked down his 
family doctor: “It took my doc-
tor from Puerto Rico calling the 
hospital to tell them these were 
all the symptoms of dengue fever. 
I was coming in with a tropical 
disease. Th ey had no idea.”
Th is gap in medical knowl-
edge was part of his inspiration 
for spearheading the new M.D./
Ph.D. collaboration between 
the School of Medicine and 
the University of Puerto Rico 
(UPR). A global context, Colón-
Ramos believes, is necessary for 
today’s health care. In this new 
program, students from the 
M.D. program at UPR can apply 
to Yale’s Combined Program in 
the Biological and Biomedical 
Sciences and will be assigned 
mentors while studying for 
their doctorates in New Haven. 
UPR students compete for spots 
along with Yale’s regular appli-
cant pool; the universities are 
looking for two or three stu-
dents per class to enroll in 
the program. 
After their fi rst year in med-
ical school at UPR, successful 
applicants will spend a summer 
at Yale completing an eight-
week lab rotation to familiarize 
themselves with the campus. 
Th ey’ll return to Puerto Rico 
for two years of training, after 
which the students will con-
duct their Ph.D. research at Yale 
and then return to UPR for the 
fi nal year of medical school. 
Th e fi rst round of applications 
tagged for the program was due 
in December 2015. Th e process 
is open to students currently 
enrolled in their fi rst year 
of medical school at UPR, as 
well as new students applying 
simultaneously to UPR and Yale 
for their M.D./Ph.D. degrees.
Training and mentoring at 
Yale will prepare the UPR stu-
dents to create a new connected 
community on their return. 
“In Puerto Rico, we don’t have 
many physician-scientists,” said 
Marcia Cruz-Correa, M.D., Ph.D., 
director of the Offi  ce of Research 
for the UPR School of Medicine. 
“Th ere are other programs that 
are trying to fi ll that void, but 
the gap is huge. Th e opportunity 
to grow is dramatic.” Cruz-
Correa hopes that the program 
will bring together medical 
professionals trained to think 
differently who will remain to 
serve Puerto Rico.
Dignitaries from UPR visi-
ted Yale last July to celebrate 
the new agreement. For mem-
bers of the delegation, the trip 
was their fi rst time to New 
Haven. Th ey met with Yale 
President Peter Salovey after a 
whirlwind day of meetings and 
tours, fi nalizing the program, 
and brainstorming more ways 
to take advantage of the new 
connections. “It’s a historical 
moment, but it’s just the begin-
ning,” said Cruz-Correa.
Th e agreement is a fi rst point 
of contact that could open up 
new opportunities for Yale’s 
medical community. It may 
serve as a springboard for future 
interactions, perhaps encour-
aging students to gain medical 
experience in the tropics as well 
as connect more deeply with the 
New Haven community. “Th ere 
are many changes going on, 
defi nitely in the United States, 
but also worldwide—think 
about Cuba,” said Colón-Ramos. 
“Patients in Puerto Rico are 
similar to a whole continent that 
lies south of the United States. 
And really, not that different 
from communities fi ve minutes 
down the road.”
“We’re all very excited and 
looking forward to the rewards 
that the students will bring 
after they fi nish,” said Uroyoán 
Walker, Ph.D., president of UPR. 
He added, “We’re training our 
next generation. And when I say 
ours, I mean the world’s.”
—Karen Zusi
ONLINE EXCLUSIVES
Harnessing the power 
of online video to 
promote health.
Full circle: a New Haven 
high school student 
returns to Yale in the 
Class of 2019.
Full stories and event 
photo galleries, as well 
as other online-only 
content, can be found 
on our home page at 
yalemedicine.yale.edu.
Dignitaries from Yale and 
the University of Puerto 
Rico, including Peter 
Salovey and UPR Presi-
dent Uroyoán Walker, 
met last summer to 
discuss a new program 
that would allow medical 
students from Puerto 
Rico to complete Ph.D. 
studies in New Haven.
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Neatly manicured suburban lawns and gardens are 
playing havoc with the frogs’ endocrine systems, 
according to a Yale study published in the Proceedings 
of the National Academy of Sciences. 
In 2012, researchers at the School of Forestry & 
Environmental Studies counted frogs at 21 ponds in 
southwestern Connecticut and found almost twice the 
proportion of females being born as in forested ponds. 
“The fact that we saw such clear evidence was aston-
ishing,” said lead author and doctoral student Max 
Lambert. Previous studies had found such effects from 
agricultural pesticides and wastewater effluent, but 
this is the first to find them in the suburbs as well. 
Because some common plants naturally produce 
phytoestrogens, Lambert said, just maintaining a lawn 
may be a source of contamination. And other species—
wood frogs, gray tree frogs, salamanders, birds, and 
turtles—may be affected as well. 
A study that analyzed data on more than 132,000 white 
heart attack patients and almost 9,000 black patients—
and used zip codes to assess income levels—found 
that the survival rate 17 years later was 7.4 percent for 
white patients, but only 5.7 percent for black patients.
White patients across all ages in low-income areas 
lived about 5.6 years after a heart attack, longer than 
the average 5.4 years for black patients. In high-income 
communities, however, the gap widened—white 
patients had a life expectancy of 7 years, compared  
to 6.3 years for black patients, according to the study 
published in Circulation, the journal of the American 
Heart Association.
The study, said lead author Emily Bucholz, M.P.H. ’09, 
M.D. ’15, Ph.D. ’15, suggests that improving socioeco-
nomic standing may improve outcomes for black and 
white patients globally, but is unlikely to eliminate 
racial disparities in health.
Some scientists see a major flaw in a recent study of 
the effects of alcohol consumption on a drug intended 
only for women.
The study of interactions between alcohol and 
Addyi, the first drug to treat female sexual dysfunction, 
enrolled 23 men—and two women.
“There is no valid reason to ignore the well- 
established biological and behavioral differences  
between men and women when conducting 
biomedical research,” said Carolyn M. Mazure, Ph.D., 
director of Women’s Health Research at Yale. “Yet it 
continues to happen.”
Sprout Pharmaceuticals, which markets Addyi, said 
in a statement that the study was designed with FDA 
guidance. “More men than women agreed to enroll 
in this kind of study,” the statement said, adding that 
Sprout plans to conduct additional studies on the 
effects of alcohol in women.
GREEN LAWNS  
AND FROGS’ SEX
AFTER A HEART ATTACK,  
A DISPARITY IN OUTCOMES
A DRUG FOR WOMEN TESTED MOSTLY IN MEN
It’s time to add gardening to the arsenal of clinical 
skills. A nutrition workshop that was developed as part 
of a new Community Engagement Curriculum had 25 
internal medicine residents preparing simple, nutritious 
dishes with vegetables harvested on a farm at Yale’s 
West Campus. The goal is for the residents to use what 
they learned to communicate more effectively with their 
patients about healthful food choices.
“We want our residents to be able to offer practical 
advice about local food systems and healthy eating 
habits, and to enhance their abilities to integrate pre-
ventative health in their regular communications with 
patients,” said chief resident Sanjeet Baidwan, M.D., 
who is leading the new curriculum with Tracy Rabin, 
M.D., HS ’10; Julie R. Rosenbaum, M.D. ’96, FW ’02; and 
Justin Freiberg of Yale’s West Campus.
The workshop is part of a Community Engagement 
Curriculum that the Yale Primary Care Internal Medicine 
Residency has undertaken, which includes communica-










































































a collection of recent  
scientific findings
Winter 2016 9
OV ER THE L AST FEW Y EA RS, as electronic medical records have become the 
norm in hospitals, clinics, and doctors’ offices, clinicians have tried to come to terms 
with the computer. Is this machine demanding their attention at the expense of the 
patient? How does a doctor engage her patient while typing data into a template?  
The tools of medicine—from the stones that Neolithic humans honed into scalpels  
to the earliest stethoscopes that emerged in the 19th century to today’s sophisticated 
imaging devices—have changed the way physicians interact with their patients.  
And those tools are changing biomedical research as well. 
At Yale and around the world such new technologies as 3D printing or biomedi-
cal engineering have advanced medical research. But scientists still rely on hunches, 
instinct, and serendipity as well as these tools. When an experiment in biomedical 
engineering yielded unplanned results, the scientists didn’t scrap their findings—
they looked for a way to use what they’d found and voilà, a new approach to sun-
screen. Another team tried to synthesize a compound found in a red sponge from the 
Caribbean to make a medicine to block HIV infection. It took eight or nine tries, and 
with each failed effort, they reevaluated and adjusted until they got it right. Physicians 
at Yale spent almost 10 years developing an artificial pancreas that would control 
insulin delivery for people with diabetes. Last summer they tried it out on a group of 
teenagers in New Haven, with dramatic results. 
In this issue of Yale Medicine we take a broad view of the machinery of medicine  
to explore the ways in which physicians, scientists, and engineers work to advance 
both their understanding of the human body and how they apply that knowledge  
to clinical care.
From raw idea to finished product  
If you have a lemon, make lemonade
Keeping the “Goldilocks” organ cool
The artificial pancreas
Human body as machine
New artery? We can print that 
The tools of medicine


























 raw idea  
to finished  
 product
Hackathons are great  
for sparking creativity,  
but turning a concept  
into a marketable  
product takes time.
By Christopher Hoffmann










At a hackathon in the fall of 
2014, a team that included 
(from left) public health 
student Sharon Wu, biomedi-
cal engineering student Shari 
Yosinski, School of Medicine 
research associate Eydis Lima, 
and biomedical engineering 
students Tobi Akindoju and 
Francis Mburu proposed a 
dermal patch for dosing and 
tracking a patient’s treatment 
during a clinical trial. Th e 
team is still pursuing the proj-
ect, which is now focused on 
developing a patch to detect 
infectious agents. “Many of 
the challenges involve time,” 
says Lima, “… being a student 
and trying to be an entrepre-
neur and fi nding time to think 
outside the box and move the 
project forward.”
From raw idea to finished product
“We’re trying to see if it’s viable and what we need to do 
to make it viable,” she said. “We are fully committed to doing 
everything to make it happen because we’ve gotten such posi-
tive feedback, and it would improve the patient experience.”
INcentiHALER’s experience is not uncommon for 
hackathon participants, said Jean Zheng, Ph.D. ’13, CBIT’s 
engineering director. Hackathons may promote innovation at 
warp speed, but turning those innovations into viable prod-
ucts usually takes several years, she said.
And that’s just fine, said Zheng and Chris Loose, Ph.D., 
CBIT’s executive director. Hackathons are about building 
excitement and energy as well as creating viable products.
“These [hackathons] are really educational at heart, and 
they can lead to some great things, and have led to some 
great things,” Loose said, adding that they’re just one part 
of CBIT’s strategy to jumpstart biomedical innovation and 
entrepreneurship at Yale. 
“The purpose of the first hackathons was to create a cul-
ture of biomedical innovation,” Zheng said. “It was raising 
awareness, creating excitement.”
And even though hackathons appear to focus on applying 
cutting-edge technology, that’s not always the case. Grand 
prizewinner INcentiHALER, for example, was about engi-
neering, not algorithms, team member Koufopoulos pointed 
out. “There are many places where just better design is 
needed,” he said. “This is not always apparent at a hack-
athon—where that might mean ‘code’ to most people. Nearly 
all of our competitors were software projects.”
Hackathons, which originated in the computer industry 
and later spread to medicine, seek to speed up innovation. 
Motivated, creative, and accomplished people come together 
for a short period, typically a weekend. They are given a 
challenge, and then they identify specific problems derived 
from that challenge and pitch solutions. At the close of the 
hackathon, judges give out awards in a variety of categories. 
The goal of CBIT, founded in 2014, is to get the Yale 
community—everyone from medical students and residents 
to engineering undergraduates and Ph.D. candidates—amped 
up about creating cutting-edge medical devices and computer 
applications. As part of its strategy, the center teamed with 
MIT Hacking Medicine, InnovateHealth Yale, CORE, and 
other sponsors to hold the first-ever Yale medical hackathons, 
one in October 2014 and the other in March 2015. 
Organizers invited diverse groups, including residents, 
doctors, nurses, doctoral candidates, and undergraduates as 
Over the course of a frenetic weekend in March, five unlikely 
colleagues—an undergrad, a nursing student, a doctoral 
candidate, an employee at a marketing startup, and a hospital 
resident—came together to design a device to help asthma 
sufferers. Inspired by a keynote speech at a hackathon, the 
initial group formed over a shared interest in asthma dosing. 
Rounding out their team at lunch, they then spent the rest of 
the weekend working like mad to complete their device.
The group labored until 10:30 Saturday night, returning 
at about 7:30 or 8 the next morning to develop a prototype. 
At one point, they sent the resident scurrying to the hospital 
for an incentive spirometer, a simple instrument that meas-
ures inhalation.
The “INcentiHALER,” as they named their device, was 
an easy fix to a widespread and vexing problem: the failure 
of many asthma sufferers to use their inhalers properly. 
Patients commonly fail to breathe in at the correct rate or 
length of time, compromising the medicine’s effectiveness. 
The team’s solution—simple, cheap, and elegant—was an 
instrument that enables users to monitor their inhalation rate.
“We focused on how design can cue a user to have 
proper technique,” said team member Angela Hasler, the 
nursing student. 
“Sometimes, innovation can just be a better-designed 
piece of plastic housing,” added team member Justin 
Koufopoulos, the marketing startup employee. “We actually 
hacked together two medical devices.”
Their device garnered the grand prize at Yale’s second  
biomedical hackathon in March, sponsored by the Yale Center  
for Biomedical and Interventional Technology (CBIT) and  
the Center for Outcomes Research and Evaluation (CORE).  
The five-member team walked away with the $500 first prize, 
and they appeared to be on their way.
Six months later, the “INcentiHALER” team is still working 
on their project, despite some bumps in the road. The top prize 
in a follow-up competition that would have provided $3,000 in 
seed money—to build a prototype and apply for a patent—went 
to another contestant, team member Catherine Jameson said. 
Summer arrived, and the team members scattered, and other 
commitments also got in the way. Jameson, for example, is 
entering her senior year as an engineering major at Yale College.
But the group isn’t giving up. Since classes resumed in 
September, the team has met twice, Jameson said. Their plan 
is to construct a better prototype, do market research, and 
then approach drug companies. 
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During the 2014 Hackathon, 
Yale College student Austin 
Muñoz (center) and team-
mates (from left to right, Matt 
Reagor, Amy Wong, and Dan 
Freed) devised a juvenile dia-
betes kit with a kid-friendly 
testing meter. Present to 
help them were Kyle Jensen, 
Ph.D., associate dean and the 
Shanna and Eric Bass Director 
of Entrepreneurial Programs 
at the Yale School of Manage-
ment, and his 5-year-old 
daughter Charlotte, who 
has type 1 diabetes. Wong, 
CBIT executive director Chris 
Loose, and Muñoz watched as 
Charlotte demonstrated how 
to administer insulin. Muñoz 
and a friend at the School of 
Architecture continued the 
project, but put it on hold af-
ter they were unable to build 
a medical-quality prototype. 
“There’s more to hackathons 
than simply building a new 
app or product in a weekend,” 
Muñoz says. “The relation-
ships formed and the skills 
learned are the true reward. 
Failure on one idea should 
never discourage someone 













From raw idea to finished product
he is happy with. Some have ended up working with the Yale 
Entrepreneurial Institute as well as his center to flesh out 
their ideas, he said. “I think it’s going extremely well.”
Another team still working on its idea called itself  
“Keep an Eye on It.” Its mobile application, developed in the 
March hackathon, would allow users to take photos of skin 
conditions, creating image libraries that physicians could 
examine and monitor, said team member Kristen D’Angelo, 
M.B.A. ’15. The app would analyze the images and provide 
a social network for patients, she said. The team is focused 
now on market research and recruiting iOS and Android cod-
ers to advance a prototype, she said. 
D’Angelo was effusive in her praise of the hackathon, 
saying she was “blown away” by the experience. “I didn’t 
picture myself standing up to propose a problem, but it was 
just such a welcoming environment,” she said. “The hack-
athon really stimulates a level of energy that lets ideas sur-
face and grow.” /yale medicine
Christopher Hoffman is a freelance writer in North Haven, Conn.
well as public health, medical, engineering, forestry, law, art, 
and business students. Both events were successes, Zheng 
and Loose said, producing a plethora of potential innovations.
But once the “hack” is over, the real work begins, they 
said. Persistence, time, and cold hard cash are needed to 
succeed. Post-hackathon, teams must build strategies to fur-
ther develop their ideas, Loose said. Especially important is 
determining a product’s market viability, he said.
“Defining the market means both how many patients are 
in need, and how big is the final market,” Loose said. “It also 
means identifying the stakeholders that need to be addressed. 
The hackathon helps start that journey.”
The emphasis on entrepreneurship and market viability is 
what sets hackathons apart, said Linda Fong, an INcentiHALER 
team member and a doctoral student in biomedical engineering. 
“Hackathons are unique in that they urge you not to focus simply 
on the invention, but to also build a viable business strategy 
around it,” she said. “Focusing on the inhaler actuator was our 
business opportunity—most companies only care about the 
drug, not the delivery.”
Of the 30 teams that took part in the two hackathons, 
about five have continued their journeys, said Loose, a figure 
Nursing student Angela 
Hasler, Yale College student 
Catherine Jameson, Justin 
Koufopoulos of Percolate, and 
a doctoral student in biomedi-
cal engineering, Linda Fong, 
won top prize for Best Patient 
Experience at a hackathon in 
March. The team redesigned 
an asthma inhaler that would 
let patients know whether 
they’re using it correctly.  
The team that devised the 
“INcentiHALER” is still working 
on the project. Their plan is 
to build a better prototype, 
do market research, and 
approach drug companies. 
“We’re trying to see if it’s viable 
and what we need to do to 











When an experiment in his lab took an unexpected 
turn, W. Mark Saltzman, Ph.D., saw a serendipitous 
opportunity, even if the Goizueta Foundation Professor 
of Biomedical Engineering and professor of cellular 
and molecular physiology and of chemical engineering 
wasn’t sure where it would lead. One of his postdocs 
had been looking at nanoparticles that would circulate 
through the blood to target tumors for drug delivery. 
Instead, he found that the particles stuck to proteins 
and tissues.
“That is not what we wanted them to do,” Saltzman 
says. Still, his team thought they might find a use for 
these sticky nanoparticles. The postdoc, Yang Deng, 
Ph.D., tested them on skin samples, and found they 
still stuck fast.
When Asiri Ediriwickrema, M.D. ’14, then a medical 
student working in Saltzman’s lab, got a look at these 
bioadhesive nanoparticles (BNPs), he saw clinical pos-
sibilities. His first thought was sunscreen. 
Saltzman’s team found a way to encase an organic 
sunscreen agent called padimate O inside the sticky 
nanoparticles. Padimate O, the active ingredient in 
many commercial sunscreens, soaks up the sun’s UV 
rays, but also soaks into the skin. Nanoparticles, on 
the other hand, are too large to pass through hair fol-
licles and pores, and they remain on the skin’s surface 
even when it’s wet. 
Such a sunscreen could answer the concerns of 
those who fear that UV-absorbing chemicals have 
harmful side effects. The next step was to find an 
expert on photodamage of the skin to see whether 
the team’s nonabsorbent sunscreen would work. The 
team knew just the person: Michael Girardi, M.D., pro-
fessor of dermatology. His lab specializes in the early 
events of skin cancer development, and in examining 
the molecular markers of direct and indirect dam-
age from UV exposure. “Yale is a small community,” 
Saltzman says. “People know what others are doing 
and you can quickly get to the person you need.”
Saltzman and his team reached out to Girardi, and 
“there was instant chemistry,” Girardi says. “And a rec-
ognition that together we could accomplish so much 
more than individually.”
The two labs joined forces to test the sunscreen  
on mouse skin and pigskin models. “We were floored 
with its performance,” Girardi says. Not only did the  
sunscreen adhere to skin for up to a full day and ab-
sorb UV rays, but it did not penetrate the skin. What’s 
more, the sunscreen, which used less than 5 percent 
of the active agent as commercial sunscreen, proved 
equally effective.
All of this means that the team is on the way to 
building a longer-lasting and less toxic sunscreen. 
Chemicals in commercial sunscreen can cause aller-
gies, and have been found in urine and breast milk. 
While such concerns as hormonal side effects have 
yet to be proven, “a lot of people feel that if they could 
avoid having these chemicals get inside the body, they 
would choose to,” Girardi says. “This technology would 
give them that choice.”
The team’s findings were recently published in the 
journal Nature Materials, with Deng and Ediriwickrema  
as co-first authors. Planning has begun for a clinical 
trial, and the team has received a pilot grant to explore 
the new technology further. They’ll be testing its effec-
tiveness with other sunblock agents and addressing 
additional safety concerns. 
Beyond that, Girardi and Saltzman see even  
greater potential for the sticky nanoparticle:  
they are looking at how it might be used to  
treat other skin conditions. “We have come  
up with more than 100 other possible  
ways to use it,” says Girardi.
—Jeanna Canapari
If you have a lemon, make lemonade
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Since the first human heart transplant nearly 50 years ago, the 
standard of care for transporting donor organs has changed 
little. A heart, kidney, or liver is harvested, cleaned, placed in a 
cooler on ice, and shipped off via ambulance or jet plane. There 
are fancier transport containers, but they can be prohibitively 
expensive or too unwieldy to travel long distances. For a partic-
ular organ—the intestine—a cooler simply won’t work. These 
intricate tubes demand more sophistication than a plastic bag 
on ice can offer. The intestine’s complex lining, or epithelium, 
“allows salts, fluids, and nutrients to go in and out on a regular 
but very regulated basis,” said John P. Geibel, D.Sc., M.D., vice 
chair and director of surgical research and professor of sur-
gery (gastrointestinal) and of cellular and molecular physiology. 
“You don’t want to have secretory diarrhea, and you don’t want 
constipation. It’s the Goldilocks organ—[the environment] has 
to be just right.” 
Besides the need for a delicately balanced environment, 
the intestine, teeming with bacteria, presents its own chal-
lenge. If the bacteria are not properly controlled, then parts 
of the intestine can fill with toxins and kill off healthy cells, 
putting the patient at further risk of infection. The problem 
with the standard ice transport method, said Geibel, is  
“that nobody is perfusing the tissue.” The intestine needs to 
be bathed in a constantly circulating liquid. 
Geibel did not have to sit on his idea for long. In 2013,  
Joseph Zinter, Ph.D., associate research scientist and lec-
turer in the School of Engineering & Applied Science, invited 
Geibel to give a presentation to his students in a medical de-
vice design class. Geibel presented his idea for an Intestinal 
Preservation Unit (IPU), for which he had no prototype.  
A team of students signed up to “take the back-of-the- 
napkin drawing to a fully functional prototype,” Geibel said. 
While intestinal transplants are not as common as 
those of the heart, lung, or kidney, slight improvements in 
transplantation procedures could mean significant gains. 
Patients who cannot absorb nutrients due to a damaged or 
missing small intestine often face one option: getting nutri-
tion through an IV or catheter. 
When he met the engineering students, Geibel presented 
them with an extremely lightweight cooler and challenged 
them to fill in the missing pieces: a reliable battery and motor, 
a system of tubes to keep liquids moving throughout the intes-
tine, and a temperature gauge and other tools for monitoring 
the status of the organ. It would be necessary to perfuse both 
the main blood supply, called the mesentery, and the lumen of 
the intestine. Within weeks, the engineering team presented 
a prototype, which contained a large battery and oversized top 
to fit the gauges and screens. “It was still kind of kludgy, but it 
was an engineering first, so we were very happy with it,” Geibel 
said. After the students graduated, Geibel kept momentum go-
ing by consulting with fellow transplant surgeons on the design. 
Soon, Geibel teamed up on another project with Jesse Rich and 
Jen Graze, students at the School of Management. In Septem-
ber 2014, the team established Revai, the company behind the 
medical device. By this time, Geibel and his team had tested 
swine organ explants in a “version 3.0” of the transport device, 
and all the animals looked healthy when examined in the histo-
pathology lab after the transport. 
To improve the design, Geibel and his team used a 3D printer 
to create a cooler top that could hold the batteries, tubing, and 
measuring devices, and would fit over the cooler. But the team 
stopped short of reinventing the wheel for a preservation solu-
tion. They used a commercially available hypothermic solution 
rather than trying to keep the liquids at body temperature.  
(The field is engaged in a fiery debate about whether hyperther-
mic, or body-temperature, transplants should be the standard 
of care rather than ice, Geibel said.) For sanitary and safety rea-
sons, the interior of the IPU, as well as the tubing and connec-
tors, are completely disposable. The Food and Drug Administra-
tion (FDA) requires this feature for all organ transport devices. 
Transporting the intestinal organ can usually occur only 
within a narrow window of two to four hours. But the Revai team 
has kept an intestinal organ alive and functioning for eight hours, 
Geibel said. “We want to get our box so that it can keep things 
alive and keep things viable for longer periods of time,” he said. 
So far, the group has reenacted an organ transplant in a 
veterinary operating room. Working with medical residents 
and fellows, Geibel and the Revai group watched while an 
animal intestine was harvested, placed in sterile towels, and 
taken to the “back table,” or what surgeons refer to as the or-
gan transplant area. The intestine was then kept in the Revai 
cooler for eight hours. The team has also tested the transport 
of five donated human intestines. Without FDA approval yet, 
the transplants could not be used for implantation in a real-
life patient. The next step, Geibel said, will be partnering with 
a high-traffic intestinal transplant center to conduct a clinical 
trial. “I think the number of transplants would go up dramati-
cally if patients knew they had a device that gave them a very 
high [transplant] success rate,” Geibel said. 
—Kathleen Raven





Ten years in its development, the artificial  
pancreas is the marriage of a sensor  
that monitors glucose levels and a pump  
that sends insulin into the bloodstream as  
needed. This device could revolutionize  
how patients manage their diabetes.
By Jill Max
Photographs by Robert A. Lisak
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Rachel Hicks scrambled up the 
wall at a New Haven climb-
ing gym last spring. Hicks 
has type 1 diabetes and was 
participating in a test run of an 
artifi cial pancreas that helps 
her monitor her blood glucose 
readings. Th e device, which 
transmits the readings to a 
smartphone device, doesn’t 
interfere with normal activities.
Last May, 15-year-old Jacob Conte was scaling a rock 
wall at City Climb Gym in New Haven. Hand over 
hand, grabbing onto holds protruding from the wall, 
he made his way up the artificial cliff. Underneath his 
clothing—indeed, under the skin on his abdomen—he 
wore a small sensor that transmitted his blood glucose 
level readings every five minutes to a smartphone 
device in his backpack. Conte has type 1 diabetes and 
requires regular infusions of insulin. The smartphone 
told an insulin pump affixed to his belt when and 
how much insulin to deliver. The pump—smaller than 
a smartphone—injects insulin under the skin of the 
abdomen through a short thin tube.
Maintaining his blood sugar control requires 
constant vigilance and dozens of decisions each day. 
When Conte plays football or snowboards, he has to 
avoid a drop in blood sugar that could make him dizzy 
or pass out. Before eating, he tests his blood sugar and 
takes insulin, but if food is delayed, the insulin might 
kick in too soon, causing his blood sugar to drop. 
Nighttime—when more than half of hypoglycemic 
(low blood sugar) emergencies occur—is especially 
perilous. If he wakes up with symptoms of hypogly-
cemia, he tests his blood sugar and eats a snack. “It’s 
kind of a burden,” he said. “Everything in my life 
revolves around it.”
Handling his diabetes is about to change. The 
climbing session was part of a four-day clinical trial 
in which Conte and four other teenagers with type 1 
diabetes took those sensors and pumps—which when 
combined with a dosing algorithm are known as an 
“artificial pancreas”—for a test run. Rather than a bio-
medically engineered organ made of tissue, the artifi-
cial pancreas is a system of devices and software that 
transmits his blood glucose level readings to the device 
that controls insulin delivery. Wearing the sensor and 
pump doesn’t interfere with Conte’s normal activi-
ties—including climbing the rock wall, playing football, 
or sleeping—and the devices are worn under his cloth-
ing, so nobody knows they’re there. Yale researchers 
have been studying the artificial pancreas for the last 
decade, but this spring was the first time it was tested 
in pediatric patients outside the hospital—here and at 
Stanford University and the Barbara Davis Center for 
Childhood Diabetes in Denver.
The artificial pancreas
ABOVE The artificial pancreas 
is a system of devices and 
software that transmit blood 
glucose level readings to a 
device that controls insulin 
delivery. Ten years in the 
making, it was developed by 
physicians and researchers at 
the School of Medicine.
OPPOSITE Anthony Alvarez 
also participated in the four-
day clinical trial last spring. 
The artificial pancreas works 
with an insulin pump to adjust 
delivery every five minutes in 
response to glucose levels.
22 yalemedicine.yale.edu

c l o s i n g  t h e  l o o p
Most of the 35 million people around the world who have 
type 1 diabetes inject themselves with insulin several 
times a day or use an insulin pump. The pump, which 
is programmed to deliver tiny doses of insulin, has 
advanced diabetes treatment. It sometimes works with 
a continuous glucose monitor (CGM) that has a sensor 
like the one Conte wore. Both devices are approved by 
the Food and Drug Administration (FDA) but work inde-
pendently of each other. The artificial pancreas closes 
the loop between the two (it’s sometimes referred to as 
a closed-loop system) by allowing the pump to adjust 
insulin delivery every five minutes in response to the 
body’s glucose levels. “The ability of the system to self-
adjust automatically while patients go about their daily 
lives would really be transformative in the lives of people 
with diabetes,” said Stuart Weinzimer, M.D., professor of 
pediatrics at the School of Medicine. Weinzimer and his 
colleagues have been working on an artificial pancreas 
for the last 10 years, with support from the Yale Center 
for Clinical Investigation. The device tested last spring, 
developed by Medtronic, is being tested at 10 centers 
(of which Yale is one) in a phase III clinical trial that is 
expected to lead to FDA approval in 2017.
The path to the artificial pancreas began in the late 
1970s, when researchers found better ways to monitor 
and control blood glucose levels. With the advent in 1977 
of the hemoglobin A1C test, known simply as A1C, doc-
tors could analyze blood sugar control over a period of 
two to three months, providing a longer view than iso-
lated blood glucose readings taken during clinic visits. 
The insulin pump—first tested in a clinical trial at Yale in 
1979—more closely resembled the way the pancreas pro-
duces insulin by delivering small doses throughout the 
day with larger doses at meals. By the early 1980s, home 
blood glucose monitoring had replaced urine testing, 
and synthetic human insulin began to replace animal 
insulin. But diabetes remained difficult to manage. “In 
those days, when we started to be able to measure more 
accurately how well controlled our patients were, most 
of the numbers would have been viewed today as totally 
unacceptable,” said Robert Sherwin, M.D., the C.N.H. 
Long Professor of Medicine, who was on the team that 
first tested the insulin pump. The pump, which gave 
patients better glycemic control, gained traction in the 
early 1990s when the landmark Diabetes Control and 
Complications Trial showed that controlling blood sugar 
levels reduced such diabetes-related complications as 
blindness, kidney failure, and neuropathy. The next 
step was to replace a finger stick every few hours with 
a sensor that would measure glucose continuously. “As 
long as insulin delivery was not linked to changes in 
blood sugar, no regimen would be perfect,” said William 
Tamborlane, M.D., professor of pediatrics (endocrinol-
ogy), another member of the Yale insulin pump team.
Sherwin tried to interest medical device compa-
nies in developing a sensor, but they weren’t ready to 
make a financial commitment. Eventually Tamborlane, 
who was also keen to develop a sensor, began working 
with Medtronic to test a CGM device that received FDA 
approval in 1999. In 2002, he recruited Weinzimer to 
Yale to look at the possibility of combining the sensor 
with a pump to develop an artificial pancreas.
a s t u d y  l a u n c h e s  a  p r o j e c t
While their experience with the pump gave Yale 
researchers a head start, other centers were also 
interested in developing an artificial pancreas. In 
2006, researchers at the University of California, Los 
Angeles, published the first study that combined sen-
sor data with an algorithm to adjust insulin infusion 
automatically. However, there was an inherent delay 
in insulin delivery: while insulin-producing cells in 
the pancreas read glucose levels every few minutes 
and secrete insulin directly into the bloodstream, the 
probe and the pump work via the fluid surrounding 
tissue, so there is a delay in both reading blood sugar 
levels and delivering insulin into the bloodstream. Still, 
the study, which showed that the system could work 
in adults, piqued the interest of the Juvenile Diabetes 
Research Foundation (JDRF), which then launched the 
Artificial Pancreas Project. The project had two arms: a 
large clinical trial of CGMs co-chaired by Tamborlane, 
which showed that the devices improved blood glucose 
control; and another, involving Yale and four other 
academic sites, to develop an artificial pancreas system.
Type 1 diabetes is typically diagnosed in children, 
so the next step was to study a closed-loop system in 
pediatric patients. In 2008, Weinzimer published the 
results of a study involving 17 children who used an 
The artificial pancreas
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artificial pancreas in the hospital. A closed-loop sys-
tem, the study showed, keeps blood sugar stable over-
night but can’t deliver insulin fast enough at mealtime. 
The solution was a manually administered extra dose at 
meals, a concept that is incorporated in the Medtronic 
device currently being tested. 
Weinzimer presented the findings of the pediatric 
study at the national JDRF conference. “People were 
crying,” he said. The artificial pancreas offered hope to 
parents who stay up at night worrying about hypoglyce-
mia, which can lead to unconsciousness and even death.
Compared to today’s artificial pancreas systems—
several are in development, but Medtronic’s is furthest 
along—the early systems were cumbersome. The sensors 
were much larger, and a radio transmitter had to be taped 
to the body and connected to a receiver plugged into a 
laptop. Today, the components are compact and the sys-
tems use wireless technology to transmit sensor readings.
a n e e d  t o  w o r k t o g e t h e r
Research is often a collaborative effort, and nowhere is 
this teamwork more evident than in the development 
of the artificial pancreas. “At first, we all did our own 
thing,” said Weinzimer. “Now we’re realizing that in 
order to demonstrate the safety and efficacy of these 
devices on a large scale, we need to work together.” 
Researchers at the University of Virginia; Boston 
University; the University of California, Santa Barbara; 
the University of Cambridge; Schneider Children’s 
Medical Center of Israel, and elsewhere are testing 
devices and designing sophisticated algorithms to fine-
tune different systems. Yale researchers have often been 
at the forefront of these efforts. Weinzimer showed that 
the artificial pancreas effectively controls nighttime 
hypoglycemia, while Jennifer Sherr, M.D., assistant pro-
fessor of pediatrics (endocrinology), is looking for ways 
to increase the system’s effectiveness at mealtimes. Says 
Francine Kaufman, M.D., Medtronic’s chief medical offi-
cer and vice president for global medical, clinical, and 
health affairs, “We rely on an institution like Yale with 
the capability of their investigators, which is immense, 
to be a push-and-pull with us.”
The artificial pancreas is based on two devices 
that already existed, yet at times, progress has been 
frustratingly slow. Resolving safety issues—such as 
delivering too much or too little insulin—was a major 
hurdle. Now increasingly tech-savvy patients are 
increasing the pressure to bring a system to the mar-
ket. In fact, the ability to tap into sensor data remotely 
began with a group of diabetes patients and family 
members who developed a software program to hack 
into sensor data via a smartphone or computer.
There is also a pressing need to improve diabetes treat-
ment despite the advances over the last 25 years. The 
recommended target hemoglobin A1C level is less than 
7 percent for adults, and less than 7.5 percent for those 
under 19, according to the American Diabetes Association. 
Yet a recent study by the T1D Exchange, a network of 
more than 70 clinics dedicated to type 1 diabetes treat-
ment and research, showed that the average adult A1C is 
8.4 percent, with adolescents averaging 9 percent.
In clinical trials, the artificial pancreas helps 
patients manage their blood sugar better with less 
effort. “He had the best control while he was on this 
closed-loop system than he’s had in the past nine 
months,” said Nicole Liedke, whose 15-year-old son 
was part of last spring’s clinical trial.
When the first iteration of the artificial pancreas 
hits the market, the device won’t be totally automatic. 
Patients will still have to instruct the pump to provide 
a dose of insulin before meals to maintain optimal 
blood sugar control, and the sensor has to be recali-
brated twice a day. But for patients like Jacob Conte, 
letting go of the reins a bit, especially at night, will 
be life-changing. His mother, Joanne, who also has 
diabetes, was with him during the clinical trial. “He’s 
making history,” she said, as tears welled up in her 
eyes. “For him and for our family, this was an unex-
pected opportunity of a lifetime.” /yale medicine
—Jill Max is a freelance writer in Trumbull, Conn.
Joanne Conte, mother of 
Jacob, 15, says that with his 
participation in the clinical 
trial, “He’s making history.”
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Human  
body as  
 machine
How Yale launched  
the Department of  
Biomedical Engineering.
By Christopher Hoffmann
Photographs by Harold Shapiro
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When Mark Saltzman (seated, 
center) began his career in 
science, there was no fi eld 
called biomedical engineer-
ing. He studied chemical 
engineering and learned how 
to develop new ways of deliv-
ering medications. Biomedical 
engineering has boomed in 
recent years and Saltzman 
leads a lab that includes bud-
ding researchers Heewon Suh 
(seated left), (standing, left 
to right) Greg Tietjen, Alice 
Gaudin, Elias Quijano, Luis 
Arana, Amanda King, Brittany 
Th ompson, Young Seo, and 
Jenny Cui (seated, right).
Human body as machine
To understand biomedical engineering, says Jon S. 
Morrow, Ph.D., M.D. ’76, HS ’77, FW ’80, chair and 
Raymond Yesner Professor of Pathology, one must start 
in the 1970s. The tools of the time confined research 
to such narrow areas as a single protein or gene. “We 
called it the streetlight phenomenon,” he said. “You 
could only study what you could see or measure, and 
it was very limited.” That began to change in the 
mid-1980s and into the 1990s. Advances in computers, 
computation, imaging, biology, and the completion 
of the mapping of the human genome in 2003 enabled 
a far deeper understanding of biological processes. 
Suddenly, scientists could view and measure much 
more. “You’ve got these massively parallel technolo-
gies that allowed you to see the whole landscape of 
processes in large scale,” Morrow said. “Instead of a 
streetlight, you had a floodlight.”
This deeper understanding elicited an “aha” 
moment—the human body looked more and more like a 
hugely complex machine. Researchers started applying 
engineering principles to biology and clinical treatment. 
“People began to realize that a biological system is just a 
complicated device, and that the engineering and com-
puter science side of things has solutions,” Morrow said.
By the late 1990s, biology and engineering had 
merged into a new and exciting discipline with the 
promise of everything from artificial limbs and organs 
to individualized drug therapies, from medical devices 
to cures for genetic diseases.
Universities around the nation were creating 
departments in this innovative area, which held enor-
mous promise for advancing medical practice and bio-
medical research. How would Yale respond?
Yale already had a head start. The medical school 
had become a leader in imaging technology—a key 
component of the new discipline. And there was inter-
est among faculty and students in pursuing this field. 
The building blocks were there; the question was how 
to assemble them.
“Not only did we have experts, not only was it com-
ing together at Yale, but it truly tapped into the needs 
of the students who wanted to pursue this,” said 
David A. Kessler, M.D., J.D., then dean of the School 
of Medicine, and now professor of pediatrics at the 
University of California, San Francisco. 
Yale was ready to jump into biomedical engineer-
ing, but key questions arose: How should Yale incor-
porate this new field within its existing areas of study 
and research? Should it create a new department or a 
stand-alone institute? If the university inaugurated a 
department, should it be part of the medical school or 
the Faculty of Arts and Sciences?
Kessler and the provost at the time, Alison F. 
Richard, Ph.D., appointed nine senior faculty members 
from the medical school and the graduate school to 
form a panel to explore the possibilities. 
After nine months of study, the committee issued 
its report in August 1999, recommending the forma-
tion of a biomedical engineering department within 
the Faculty of Arts and Sciences and tied to the medical 
school. The committee rejected the stand-alone model 
favored by some institutions. “They become insular,” 
said Morrow, who served as one of the committee’s 
two co-chairs along with Bruce McClennan, M.D., pro-
fessor emeritus and biomedical imaging. “They talk 
to themselves. You never learn anything by talking to 
someone who does the same thing you do.”
The new department would have its own faculty; 
and faculty from the medical school and elsewhere at 
Yale would hold secondary appointments in biomedical 
engineering. “That was a very important piece, allow-
ing faculty the freedom to participate across schools 
and disciplines, and across graduate and professional 
and undergraduate boundaries,” Kessler said.
The university, including then-President Richard 
C. Levin, endorsed the committee’s recommendations. 
“Everyone got behind it,” Kessler said. “It was across 
Yale. Nobody owned it and yet everybody owned it.”
w e d o n’t  wa n t  t o  b e  a n  av e r a g e  p r o g r a m
Yale’s new Department of Biomedical Engineering 
opened its doors in 2003 within the School of 
Engineering and Applied Science. The university lured 
W. Mark Saltzman, Ph.D., the Goizueta Foundation 
Professor of Chemical and Biomedical Engineering, 
and Cellular & Molecular Physiology, from Cornell 
University to serve as chair. When Saltzman graduated 
from Iowa State in 1981, biomedical engineering was 
not yet an established field, so he earned his under-
graduate degree in chemical engineering. A pioneer 
yalemedicine.yale.edu28
In 1999, pathologist Jon Mor-
row co-chaired a committee 
to determine whether Yale 
should create a department 
dedicated to biomedical engi-
neering. Advances in comput-
ers, computation, imaging, 
biology, and the completion 
of the mapping of the hu-
man genome in 2003, says 
Morrow, enabled a far deeper 
understanding of biological 
processes and helped create 
the fi eld.
Human body as machine
Elias Quijano got hooked on 
biomedical engineering while 
a student at Yale College. 
Now a first-year student in 
the M.D./Ph.D. program, he’s 
working in Saltzman’s lab 
on new ways to deliver HIV 
medications.
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in drug delivery and tissue engineering systems, 
Saltzman relished the chance to build a department 
from scratch. 
“I liked the idea of starting something new at a place 
where I was pretty confident it would be successful,” 
said Saltzman, whose team devises novel methods for 
the controlled delivery of drugs, proteins, and genes. 
Saltzman’s initial goals were to hire outstanding 
faculty and build a curriculum. He hired slowly, know-
ing that each new person would have a significant 
effect on the overall department culture. Given that 
the department would never be very large—today it 
has about 15 members—Saltzman gave a lot of thought 
to its focus. “We picked areas that we wanted to excel 
in,” he said. 
Saltzman settled on four: imaging, an area in which 
Yale was already a leader; biomolecular engineering, 
Saltzman’s specialty, applying engineering to biological 
systems; biomechanics, understanding how the body 
works from a mechanical engineering perspective; and 
systems biology, studying biological systems as a net-
work of components that interact with one another.
A dozen years later, the department is thriving, 
Saltzman said. It has developed largely as its founders 
envisioned—multidisciplinary, collegial, integrated 
with the medical school, and committed to under-
graduate education. The department confers about 
40 undergraduate and 10 graduate degrees a year, with 
an average of 50 doctoral students at some stage of 
their studies at any given time. “We don’t want to be 
an average program,” said Saltzman, who ended his 
12-year tenure as chair on July 1. “We want to be an 
outstanding program. Even though we are a young 
department, I think we are judged as among the best 
programs in the country. This happened fast for us 
because of the strength of Yale.”
The program has produced numerous startups 
and endless innovation. Saltzman cites the work 
of Rong Fan, Ph.D., associate professor of biomedi-
cal engineering. Fan uses nanotechnology to “talk 
to cells”’—employing tiny sensors to take dozens of 
measurements of an individual cell. Saltzman also 
mentions Laura E. Niklason, M.D., Ph.D., professor 
of anesthesiology and biomedical engineering, who 
joined the biomedical engineering faculty a decade 
ago. She credits Yale with allowing her to pursue what 
some might consider her “outlandish” research in lung 
regeneration. “Yale’s culture is pretty good at embrac-
ing new ideas,” Niklason said.
Saltzman adds that biomedical engineering isn’t just 
high-tech. A whole other aspect involves engineer-
ing a complex device, such as a ventilator for newborn 
babies, into something so simple and foolproof it can 
operate in a third-world hospital without reliable 
access to electricity—a project now underway in the 
department under the guidance of Anjelica Gonzalez, 
Ph.D., the Donna Dubinsky Associate Professor of  
Biomedical Engineering. Gonzalez teaches a course—
called Biotechnology for the Developing World—that 
introduces students to engineering design for low-
resource environments in global health.
a pa s s i o n  f o r  b i o m e d i c a l  e n g i n e e r i n g
In many ways, Elias Quijano embodies the way in which 
Kessler, Morrow, Saltzman, and others envisioned the 
program. The son of immigrants from Ecuador and 
Colombia who never attended college, Quijano arrived 
at Yale College in 2008 with no interest in science. 
Needing to fulfill a requirement, he took Saltzman’s 
course, “Frontiers of Biomedical Engineering.” “In Dr. 
Saltzman’s class, I developed a passion for biomedical 
engineering and decided to study it.,” Quijano said.  
“It allowed me to appreciate the contributions that an 
individual can make to medicine.”
After graduating in 2012, Quijano worked on gene 
therapies for cystic fibrosis in Saltzman’s lab. Now he is 
a first-year student in Yale’s M.D./Ph.D. program.  
“I don’t know exactly where that’s going to take me,” 
Quijano said, “but I’m confident that my engineering 
education will provide me with the skills to bridge the 
gap between the lab and the clinic, between research 
and medicine.” /yale medicine
Christopher Hoffman is a frequent contributor to Yale Medicine.
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Mark Michalski, M.D., HS ’15, on call late one night in 2013, 
was browsing through Wired when he came across an 
article about 3D printing. It is, as the name suggests, a tech-
nology for printing—not ink on a sheet of paper but struc-
tures made of diverse materials in three dimensions. Then 
a radiology resident at Yale-New Haven Hospital, Michalski 
spent many working hours examining cross-sectional 
images of the human body and body parts. These im-
ages, taken from computed tomography (CT) and magnetic 
resonance imaging (MRI) scans, depict the body as if it were 
cut up into many thin slices; taken together, they represent 
three-dimensional structures. Most of the time, surgeons 
scroll through these images to create mental pictures of the 
anatomy that they will meet in 3D only in the operating room. 
3D printing, Michalski realized, offered a new possibility: 
custom-printed 3D models, which surgeons could handle 
and experiment with, of the structures that they would later 
cut, stitch, and screw together. 
“I thought to myself, ‘Well, I have a lot of the raw materi-
als here; I wonder if I can just start printing things,’ ” recalls 
Michalski. “Of course, it wasn’t that simple.”
Since then, Michalski and other radiologists at Yale have 
used 3D printing to make models in both plastic and plaster 
of knees, feet, pelvises, shoulder blades—“just about any-
thing bony,” says Michalski. Physicians use these models to 
teach young doctors, plan surgeries, and communicate with 
patients. In the department of surgical research, doctors 
are using Bio3D printers, which print live cells, to make not 
models but the organs themselves, starting with blood ves-
sels. 3D-printed organs, doctors hope, could eventually be 
used in organ transplants.
Invented in the 1980s, 3D printers build up objects layer 
by layer. The printer draws out one layer of “ink” (which can 
be plastic, metal, plaster powder, wood composite, even 
chocolate); the platform moves downward, and the printer 
adds another layer atop the first. Successive strata form a 
three-dimensional object in the same way that a surgeon 
may use multiple cross-sectional images to envision a 3D 
form. The printer follows a digital template; and luckily for 
doctors, software can turn radiological data from MRI and 
CT scans into these very guides.
In 2013, the raw materials that Michalski had at his 
disposal included not just troves of radiological scans but 
also 3D printers in the Yale Center for Engineering Innova-
tion and Design (CEID). The CEID has five 3D printers, three 
of which are available to any Yale student or faculty member. 
These open-access printers, produced by the New York City-
based company MakerBot, extrude melted plastic through a 
heated tip that moves around the platform, creating a design 
in the same the way a baker writes with frosting on a cake.
In mid-2013, Michalski started printing anatomical 
objects on the MakerBot printers; his first print was a blue 
plastic model of the chambers of a child’s heart. It was not 
long before Michalski began to collaborate with the CEID’s 
assistant director, Joseph Zinter, Ph.D., M.H.S. ’11, to 3D-
print models that could help surgeons. In June 2013, for 
example, they printed a model of the tumor-invaded tibia 
of a patient scheduled for surgery at Yale. “We brought the 
model to the orthopaedic surgeon and said, ‘This is the case 
you have on Thursday,’ ” recalls Zinter. The model helped the 
surgeon plan an operative approach that would avoid cutting 
the patient’s patellar tendon, says Zinter. 
Based on the success of Michalski’s work at the CEID, 
the Department of Diagnostic Radiology acquired its own 3D 
printers in 2014. Radiology uses powder printers, a differ-
ent type of 3D printer from those at the CEID. The powder 
printer lays down a bed of powdered plaster and the printer 
tip dispenses glue, causing the powder to stick together 
where the tip writes. By the end of the print job, the object 
is essentially buried in plaster dust, which supports the 
structure as it is being printed; the unused powder is then 
vacuumed away. (Since mid-2015, Michalski has worked full 
time for a medical device company, the Butterfly Network, 
of which he is president. As a research affiliate in the hospi-
tal’s diagnostic radiology department, though, he maintains 
his ties to Yale and still does the occasional 3D print.)
Elliott Brown, M.D., HS ’12, FW ’13, who has led ra-
diology’s 3D-printing program since Michalski left Yale, 
explained how 3D printing helps physicians with their cases. 
Some things are easy to understand from looking at a radio-
logical image, says Brown, but in tricky cases, “a 3D model 
is very helpful, because you get depth perception and you 
get proprioception, meaning you can understand the shape 
of an object by its feel.” Since it’s possible to drill into plaster, 
the models also allow orthopaedic surgeons, who may need 
to screw a patient’s bones back together, to test various 
surgical approaches.
Beyond models, researchers want to print living organs 
for patients awaiting organ transplants. In the ideal case, 
these could be printed from cultured cells taken from the 
New artery? We can print that
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recipient, eliminating both the wait for a donor organ and 
the risk of immune system rejection. 
This past summer, Yale’s department of surgical 
research joined the effort to 3D-print organs when they 
acquired a Bio3D printer through a partnership with the bio-
printing company Organovo. John Geibel, D.Sc., M.D., M.S., 
vice chair of surgery, director of surgical research, profes-
sor of surgery and of cellular and molecular physiology, 
and his colleagues began by printing blood vessels using 
mixtures of rat smooth muscle, fibroblasts, and endothelial 
cells. In a laboratory hood, the bioprinter lays down the “bio 
ink,” strips of cells resembling ground meat, supported by 
strips of a water-based gel. The result: a cylinder of cells 
around a gel interior, which later can be removed to become 
the lumen of the blood vessel. The next benchmark, says 
Geibel, is to implant 3D-printed vessels into rats.
Eventually, Geibel would like to print a liver. During his 
career, Geibel hopes to create a 3D-printed “assist liver” 
that could be transplanted into patients and help them sur-
vive while they await a donor’s liver. “If we get that far,” says 
Geibel, “it’s not impossible to think that we could eventually 
create a complete replacement organ.”
—Ashley P. Taylor
A year ago Mark Michalski 
was fi nishing up his 
residency. Now he’s heading 
a startup with millions of 













From the first stone blades of the Neolithic 
age to electronic health records, medical 
advances have altered the relationship 
between doctors and patients. And some-
times the technology has overwhelmed 
the human touch.
By Jenny Blair, M.D. ’04
Pamela Moore Photo

There’s more than one way to secure an airway. 
Emergency medicine residents and paramedics learn 
early about the tools at our disposal to ensure that air 
gets into a patient’s lungs. In my residency, we called 
these tools airway toys, especially when we tried them 
out at conferences. The right toy could save a life, and 
there were always newfangled ones coming along.
So it goes throughout medicine today, with its explo-
sion of new medical devices and the increasingly ubiq-
uitous computer. Biologically, our bodies are largely 
structured as they were in the Neolithic age, when prac-
titioners used stone blades to carve holes in the skulls 
of patients—who often survived the procedure. But our 
instruments are now infinitely more complex, our era 
the most tech-saturated in history. Many of us owe our 
lives to the tools of medicine—including those that have 
brought unforeseen consequences. 
Diagnostic devices, for example, have quietly and 
profoundly changed the doctor-patient relationship. 
Such devices haven’t been around long, and the first 
ones were comparatively simple. René Laennec’s 1816 
stethoscope was a wooden tube; it impressed many, 
not least those who were shy about laying an ear on 
the chests of buxom women, but some physicians con-
tinued to rely on the old technique and on feeling the 
patient’s pulse. In 1868, Carl Wunderlich published a 
landmark work on monitoring body temperature—a 
proposal that did not go over well with some of his 
German colleagues steeped in a philosophical rather 
than observational approach to medicine. Hermann 
von Helmholtz used his ophthalmoscope to observe 
the retina in 1850, wowing colleagues the following 
year at the Great Exposition in London; in 1868,  
John Aylwin Bevan wrote to The Lancet that he had 
“discovered” a candle-powered esophagoscope, with 
which “morbid growths, &c., can be clearly seen.”  
In the meantime, laboratory medicine was beginning 
to flower, thanks in part to the mid-19th-century 
adoption of the medical microscope and advance-
ments in histology over the latter half of that century. 
Scipione Riva-Rocci gave the world the sphygmoma-
nometer for measuring blood pressure in 1896, and 
The tools of medicine
In the mid-19th century,  
Hermann von Helmholtz 
invented the ophthalmoscope, 
which allowed physicians to 
observe the retina.
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Willem Einthoven introduced the electrocardiograph—
it weighed 600 pounds and required five assistants 
to operate it—in 1902. Wilhelm Roentgen’s X-rays 
debuted in 1895, and dominated medical imaging until 
the 1950s, 60s, and 70s saw the first ultrasounds,  
CT scans, and MRIs. 
i s  d i a g n o s i s  a  z e r o -s u m g a m e ?
Today, among practitioners trained in modern imaging 
and lab tests, practicing without them can seem almost 
unthinkable. In 2005, doctors in the United States 
ordered an estimated 1 billion needle punctures of 
veins for blood sampling, and by 2007 they were order-
ing 80 million CTs a year. 
Such wizardry can make diagnosis seem like a zero-
sum game. Why cultivate the difficult orally transmit-
ted art of physical diagnosis when it’s so much quicker 
and more accurate to order a study? In the process, 
costs go up, along with such unintended consequences 
as radiation-induced cancers from too many CT scans. 
Or the patient can find himself parceled, body part 
by body part, system by system, amongst specialists. 
Or “incidentalomas” pop up, unexpected findings that 
may not truly warrant treatment, but that can cause 
anxiety and even harm from further testing. There is 
also a loss of resiliency, something any tech-saturated 
physician discovers if she tries practicing in a develop-
ing country and realizes she’s forgotten the difference 
between S3 and S4 heart sounds. Back at home, we may 
be just a power outage or hurricane away from discov-
ering how much our effectiveness depends on these 
technologies.
In fact, older physicians like Irwin Braverman, 
M.D. ’55, HS ’56, professor emeritus of dermatology, 
are concerned by what they see as a loss of physi-
cal diagnosis acumen among today’s house staff and 
attendings—a phenomenon historians of technology 
call deskilling. When Braverman trained, the most 
admired senior physicians were highly observant and 
sharply deductive. With X-rays their main confirma-
tion tool, they had to be. “Physicians were using all 
their senses plus whatever images they had to pull 
things together. They were actually pretty good at it,” 
Braverman says. Today, by contrast, he says, “the doc-
tors’ cognitive skills keep declining because they rely 
so much on technology.” (Ironically, at least one group 
of technologies—simulators—can be used to train stu-
dents in old-fashioned physical diagnosis skills.)
t h e  s k i l l s  h u m a n s b r i n g  t o  t h e  ta s k
At worst, too much specialty testing can lead to a 
potentially fatal valuing of abstraction over examina-
tion, a sort of cognitive abandonment of the patient. 
Thomas P. Duffy, M.D., professor emeritus of medicine, 
recalls a patient with fever, back pain, and neurological 
findings whose physical exam suggested an epidural 
abscess—an emergency that requires immediate treat-
ment. Yet that treatment was delayed by the provid-
ers’ wish to schedule an MRI to confirm the diagnosis. 
Somehow, the diagnosis seemed not to exist until a 
machine said it did. 
Yet these tests can uncover crucial information 
that no physical exam ever could. The question, says 
historian Joanna Radin, Ph.D., is how to combine 
knowledge from scan results and the expertise of an 
experienced physician, rather than reflexively valuing 
one kind of knowledge over the other.  
“There are many, many examples of the ways in 
which technology has been introduced in a way that 
doesn’t honor the skill and the richness of knowledge 
that humans bring to a task,” says Radin, assistant 
professor in the history of medicine, of anthropol-
ogy, and of history. “Which isn’t to say that we should 
reject technology—but it’s worth considering what 
ways we want to deploy technology.”
w h e n o l d  p r a c t i c e s  fa l l  b y  t h e  way s i d e
In the 1980s, amid bitter controversy, laparoscopy 
transformed surgery. Inspired by gynecologists who 
were employing the technique for tubal ligations in 
the late 1970s, some pioneering surgeons tried it a 
few years later for gallbladder removal and were vili-
fied by their colleagues. What was then the standard 
open surgical technique for gallbladder removal had 
remained essentially unchanged since the 1940s. 
Ultimately, though, laparoscopic cholecystectomy 
became the gold standard for uncomplicated gallblad-
der disease, driven by patient demand and studies 
finding advantages like less postoperative pain and 
shorter hospital stays. 
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Those attending surgeons who did make the switch 
had to learn laparoscopy on the job; one study in 
Germany found that this catching up meant temporar-
ily depriving trainees of available cases. 
There’s another problem, one that runs parallel 
to what physicians like Braverman are noting: these 
days, so many routine cholecystectomies are done via 
laparoscopy that younger surgeons seldom use the 
open technique any longer. If complications force them 
to “convert” to the once-routine open procedure, the 
surgeons’ inexperience could lead to patient harm. In 
2012, a group of Harvard surgeons wrote that for that 
very reason, open cholecystectomy is no longer the safe 
alternative it once was. Last year, this situation led a 
team of London historians to reenact 1980s-era open 
cholecystectomies in a period operating suite with the 
aid of retired surgeons and nurses, in the hope of pre-
serving knowledge of the older technique.
technology is neither good nor bad—nor neutral
A koan-like axiom of the history of technology pro-
posed by historian Melvin Kranzberg, Radin adds, 
holds that technology is neither good nor bad—nor is  
it neutral. Its value is all in how you roll it out.
There might be no more heated debate about that 
idea today than the one that is taking place over  
electronic health records (EHRs). As practitioners  
and hospitals across the country scramble to switch 
from paper records to meet federal benchmarks,  
some commentators are pointing out unintended con-
sequences. The promise of convenient record-sharing 
and streamlined billing, not to mention access to  
clinical data for studies, has been offset by design flaws 
(like defaulting to the wrong measurement units);  
high cost; and the alienating, time-consuming task  
of data entry. It’s a less than ideal doctor-patient 
encounter, after all, if the doctor is chiefly communi-
cating with a computer monitor.
Yet EHRs, Radin says, can offer an opportunity 
“to bring the technology more in alignment with 
what makes a physician an excellent physician.” For 
instance, a system may automatically rate physicians 
for speed, forcing them to hurry through history-
taking. What if, Radin asks, those same programs rated 
the physicians for the number of adjectives they chose 
to describe the patient, guiding them to record a more 
richly descriptive history?
Lisa Rosenbaum, M.D., made a similar point in an 
October 22, 2015 New England Journal of Medicine 
perspective piece. 
“We measure many things that have no value to 
patients, while much of what patients do value, includ-
ing our attention, remains unmeasurable,” Rosenbaum 
wrote. “The technology will support and improve 
medical care only if it evolves in ways that help, rather 
than hinder, us in synthesizing, analyzing, thinking 
critically, and telling the stories of our patients.”
Better alignment of technology in this way requires 
not only conversations between users and designers, but 
also paying attention to what’s being lost, Radin says. 
“Technology is always about changing human relation-
ships,” she says. In the humble stethoscope, there is 
precedent for such thoughtful design. In its modern 
form, says Duffy, the stethoscope’s tubing isn’t the 
optimum length for good acoustics: if it were, it would 
be shorter. Rather, it represents a compromise between 
good acoustics and the need to honor the patient’s per-
sonal space. The modern stethoscope can create an inti-
mate yet respectful encounter, one that preserves the 
solemnity and grandeur of professional mastery.
During auscultation, Duffy says, “No matter what 
I hear, the patient is fascinated and always asks me, 
‘What did you hear, doctor?’ … This is the beginning of 
a wonderful trust, because of the hovering, listening, 
[and] attention. It’s quiet, and it has a magic all its own. 
We shouldn’t give that up.” /yale medicine
Jenny Blair, M.D. ’04, is a frequent contributor to Yale Medicine.
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What if there were a natural compound that could prevent 
HIV infection without damaging living cells? Batzelladine 
B is such a compound. It was discovered in the late 1990s 
in the red sponge from the Caribbean. But the process of 
synthesis, or recreating it in the lab, proved complex and 
lengthy. Seth Herzon, Ph.D., professor of chemistry and 
pharmacology, whose lab focuses on natural product syn-
thesis, recently discovered a new and efficient route for syn-
thesizing batzelladine that makes it more readily available 
for HIV-related research. With the shorter synthesis comes 
the ability to modify the structures of batzelladine more 
easily and make improved derivatives with better properties.
Batzelladine’s advantage is that it blocks the HIV protein 
GP120 as it tries to bind with CD4 receptors on the mem-
branes of immune system T cells. Once the protein binds, 
the virus then injects its genomic information into the cell 
where it replicates, bursting the T cell and spreading infec-
tion. Batzelladine binds to the T cell’s CD4 receptors and 
prevents the HIV protein from fusing to the cell membrane.
Herzon’s team, which included postdoctoral associate 
Brendan Parr, Ph.D., and graduate student Christos Economou, 
hoped to find a faster way of synthesizing batzelladine. One 
hurdle was that batzelladine contains nitrogen, an element 
with conflicting attributes. It helps compounds interact with 
biological systems, but it can also be unpredictable—requiring 
extra steps to temper its reactivity. So the team used stable 
ringed compounds called pyrroles as the molecular starting 
point. “Making this connection allowed us to develop a very 
short route that used about half of the steps other people have 
needed to create similar structures,” Herzon explained.
Throughout the process Parr and Economou worked 
through each reaction and then met with Herzon to brain-
storm changes. “We began with what we thought would 
happen and then ran the reaction. But as is common in 
synthesis, what we thought would happen usually didn’t 
occur,” said Herzon. “First, we had to understand what had 
happened. Then, we tried to adjust how we were thinking 
about the structure in order to think of new reactions that 
might do what we wanted them to do.” For example, batzel-
ladine consists of two fragments. While the first fragment 
was created quickly, it took eight or nine approaches to the 
second fragment before finding one that worked.
Just as no plan of battle survives the first shot, experi-
ments require some artistic capacity and intuition. “It takes 
a bit of faith, and willingness to go on your hunches,” he 
Seth Herzon discovered a com-
pound found in red sponge that 
could prevent HIV infection 
without damaging living cells.
A hunch leads to an anti-HIV compound
said. For example, they had a hunch that they could control 
nitrogen’s unpredictable nature until the last step in the 
plan. This allowed them to consolidate 10 discrete chemi-
cal reactions into a single step. “We didn’t initially plan this,” 
Herzon said. “But as the synthesis evolved we recognized 
that [multiple reactions] were possible and we were able to 
go for it.” 
Once the synthetic plan was solidified, it was important 
to ensure that each step and reaction yielded the maximum 
amount of the chemical building block for the next step in 
the process. Though time-consuming, this phase resulted in 
a synthesis that requires only 15 steps and provides a good 
quantity of batzelladine.
The project took about 18 months; batzelladine can now be 
synthesized in about two weeks. This September, an interdis-
ciplinary team, headed by Karen Anderson, Ph.D., professor of 
pharmacology and of molecular biophysics and biochemistry, 















  Greek drama’s  
lessons for veterans
It’s the fifth century BCE, and 
Athens is in turmoil. Civil war, 
plague, and revolts against 
the Persian Empire have left 
the countryside in tatters. By 
the end of the century, half 
the population is dead and 
the city has emptied its trea-
sury battling Sparta in the 
Peloponnesian War—but for 
Peter Meineck, Ph.D., clinical 
professor of classics at New 
York University, during his 
lecture in August at summer 
Psychiatry Resident Grand 
Rounds, “Combat Trauma 
and the Ancient Greeks: Does 
Ancient Greek Literature 
Reflect a Society Dealing with 
the Stresses of War and Can It 
Be Used to Help the Veteran 
Community Today?”
In the midst of conflict 
and disease, Athenians 
found solace in their the-
aters. Sophocles, Euripides, 
and Aeschylus wrote the 
plays we remember today 
as highlights of Greek trag-
edy: Antigone, Oedipus 
Rex, Medea, Ajax, to name a 
few, in addition to Homer’s 
Odyssey and Iliad. These 
playwrights told legends 
of Greek heroes—heroes 
dealing with insanity, 
depression, anger, and 
  A classics professor  
helps veterans of war find their  
 voice through literature.
  By Karen Zusi
The sea battle near Salamis was 
a decisive victory of the Greco-
Persian War in 480 BCE, when Greek 
city-states united under Themis-
tocles defeated King Xerxes of the 
Persian Empire. The 19th-century 
German painter Wilhelm von  
Kaulbach depicted the battle that 
took place between the Greek 
mainland and the island of Salamis.
the artistic Athenians, even 
in troubled times, theaters 
remain open and festivals are 
celebrated every year to honor 
the gods. “Why on earth does 
this stuff continue? It was 
regarded as so important, and 
so central to public life, that 
it was the last thing that they 
were going to stop doing,” said 
homecomings tainted by the 
traumas they had experi-
enced in mythical wars. 
Plays were performed 
in large open-air spaces by 
actors hiding their faces 
behind masks. Meineck posits 
that the whole affair was a 
visceral, cathartic experience 
not found in today’s enter-
tainment industry, where 
audiences are expected to 
keep their emotional reactions 
private. The ancient theaters 
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As long as humans have waged war, 
they have suffered from the psycho-
logical trauma of the battlefield. In 
World War I this trauma was known 
as “shell shock.” By the time of World 
War II it was called combat stress 
reaction or battle fatigue. Through-
out history artists have depicted the 
horrors of the battlefield in paintings, 
plays, novels, songs, and film.
RIGHT During the Civil War, reactions 
to the battlefield were known as 
“soldier’s heart.” In 1862, two pho-
tographers hired by Matthew Brady 
produced the first images, taken 
after the Battle of Antietam, to show 
dead bodies on the battlefield. The 
“Bloody Lane” was a sunken road 
so crowded with dead bodies that it 
slowed the Union advance. 
BELOW The Imperial and Royal War 
Press Bureau of the Austro-Hungar-
ian Army, produced thousands of 
photos from the front lines, includ-
ing this one of a medical aid station.
opportunity to connect with 
those who may have served 
in Vietnam or Korea. Such 
informal mentorship wasn’t 
part of his original vision, but 
Meineck said it’s helped cre-
ate a deeper sense of commu-
nity. “I try to be really honest 
about what we’re trying to 
do, which is really just create 
a conversation,” he added.
Meineck, a native of Great 
Britain, served in the Royal 
Marine Reserve himself as a 
teenager during the Cold War, 
though he never saw com-
bat. But he has met count-
less combat veterans who 
understand Greek tragedies 
on a level different from that 
granted by years of academic 
study. Some have found per-
sonal moments of catharsis 
in reading the ancient works: 
“One Vietnam veteran really 
broke down and said,  
‘I thought I had dealt with 
this. After 40 years, I thought 
it had been dealt with,’ ” 
recalled Meineck. “And it 
was very shocking to him 
that it hadn’t been.” Their 
experiences allow veteran-
actors to bring a new depth 
to the plays, offering an 
intensity and wisdom that 
even the best civilian actors 
might otherwise be miss-
ing. “You pick up the vibe of 
these men and women,” said 
Meineck. “They have told me 
that they’re getting to speak 
through this drama—and it’s 
really quite indescribable, but 
it’s remarkable.”
also served as a place of heal-
ing; they were often situated 
next to hospitals and healing 
centers. “It was their form 
of mass cultural therapy,” 
Meineck said. 
Given the history of 
ancient Greece, these dramas 
would have been written, 
performed, and viewed by 
combat veterans—and now, 
Meineck works to connect 
modern-day veterans with 
the classics. “Even if they 
don’t know anything about 
the Greeks, they get it,” he 
said. “[The plays] speak to 
combat veterans, and I think 
they make it okay for combat 
veterans to speak for them-
selves, if they want. They 
know that these are culturally 
valued artifacts—so if these 
culturally valued artifacts 
seem to talk about their expe-
riences, it actually creates an 
environment where it’s okay 
for them to talk.”
For the last eight years, 
Meineck has directed 
an organization called 
YouStories, which brings 
veterans to the stage to 
perform Greek tragedies 
and connect with civilian 
audiences in a nuanced way. 
The program isn’t offered 
by trained therapists, but 
Meineck often hears that per-
forming together has helped 
veterans process their experi-
ences. The program also gives 
younger men and women 
returning to the United States 
from Iraq or Afghanistan an 
RIGHT The term "posttraumatic 
stress disorder" came into use 
in the late 1970s to describe the 
trauma of veterans of the Vietnam 
War. U.S. Army helicopters covered 
a South Vietnamese infantry 
advance with machine gun fire 
in March 1965, as they moved to 
















“Why so many public health 
groups are trying to block them 
is beyond me,” said Siegel. 
“Cigarettes are highly toxic and 
kill 400,000 people a year, while 
e-cigarettes are not particularly 
harmful and they’re helping 
many people quit.”
During his medical internship 
at Berkshire Medical Center in 
Pittsfield, Mass., Siegel saw that 
most people are admitted to the 
hospital for preventable reasons: 
smoking, alcohol, drugs, poor 
diet, and lack of exercise. “We 
can counsel every patient who 
walks in the door about smok-
ing,” he said, “but wouldn’t it be 
more effective to have mass public 
health campaigns that reduce 
smoking? You’ll have a much larger 
impact on the public’s health.” 
That’s what led him to a 
fellowship in the Centers for 
Disease Control and Prevention’s 
Office on Smoking and 
Health after residency. “That 
   Alum sees place for  
e-cigarettes in smoking cessation
»
I N T H E F I E L D OF T OB AC C O C ON T ROL , Michael B. Siegel, M.D. ’90, is a lone 
wolf. The Boston University public health professor stands at odds with most 
of his public health colleagues on one matter: e-cigarettes. 
experience convinced me that  
I wanted to pursue an academic 
career in public health.” But 
smoking cessation had been 
Siegel’s passion since he was an 
undergraduate at Brown. There 
he lobbied to make Rhode Island 
the 13th state to ban smoking in 
the workplace. During medical 
school, he lobbied for tobacco 
control laws in Connecticut.
Siegel believes that e-cigarettes  
can make the big public health 
impact he’s been waiting for. 
Users inhale vaporized liquid 
nicotine from the battery- 
operated devices that some-
times resemble cigarettes. 
Nothing burns. There is no 
tobacco, no smoke, only vapor. 
Hon Lik, a Chinese pharma-
cist and former heavy smoker, 
invented e-cigarettes as a 
smoking cessation device in 
2003 after his father died of 
lung cancer. Since the prod-
ucts came to the United States 
in 2007, the FDA has regulated 
them as tobacco products. A 
misnomer, Siegel laments, that 
undermines the good the prod-
ucts could do. 
 “More than 90 percent of 
smokers who try to quit fail. 
E-cigarettes work for them 
because they simulate actual 
smoking behavior—the hand 
motion, the throat hit, the  
holding of the cigarette, even 
some of the social aspects. You 
can [vape] with others in a 
group,” Siegel said. 
But the devices are not FDA-
approved for smoking cessation, 
so ads can’t say that vaping is 
safer than smoking or that  
e-cigarettes help smokers quit. 
“You have a product that could 
help the public, and you’re not 
allowed to tell them what it does,” 
Siegel said. “No one is arguing 
that e-cigarettes shouldn’t be 
regulated. The question is, How?”
To sell their wares, e-cigarette  
makers resort to the same 
advertising themes that tobacco 
companies use—sex, freedom, 
and independence. This, said 
Siegel, tells smokers who might 
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Michael Siegel’s thinking 
on e-cigarettes runs 
counter to prevailing 
views in the public health 
community. He believes 
that they are safer than 

















otherwise try e-cigarettes that 
these devices are just more of 
the same. 
Labeling e-cigarettes as 
tobacco products, Siegel worries, 
amounts to a missed opportunity 
for smokers. “Th e best thing is 
to quit smoking completely, but 
very few people are able to do 
that.” For the rest, Siegel argues, 
e-cigarettes are far less harmful 
than tobacco cigarettes. “You’re 
no longer inhaling tens of thou-
sands of chemicals from tobacco 
smoke, including more than 
60 known human carcinogens.” 
Siegel doesn’t argue that the 
products are completely harm-
less. Nicotine alone may pose 
heart risks. It’s about harm 
reduction for those who would 
otherwise smoke for life, he said. 
A 2015 review published in BMC 
Medicine cites emerging evi-
dence that smokers who switch 
to e-cigarettes show improve-
ment in airway function and 
respiratory symptoms. A recent 
study in the International 
Journal of Environmental 
Research and Public Health
showed similar outcomes in 
smokers with asthma who 
switched to vaping. 
“Th ere is a deeply entrenched 
ideology in tobacco control that, 
one, anything that looks like 
smoking could not possibly be 
endorsed, and two, any addic-
tion is terrible,” Siegel said. 
Th is makes would-be vapers 
think, “Why bother?” Siegel adds.
Perhaps the only issue 
on which Siegel and his col-
leagues see eye to eye is kids. 
E-cigarette opponents argue 
that the products should be 
banned or tightly regulated so 
that kids don’t take them up. 
“I’m sure they will ban the sale 
of these products to minors, 
and to me, that’s a no-brainer. 
It makes sense.” 
But that’s where Siegel’s and 
his peers’ common ground ends. 
E-cigarette opponents argue that 
vaping breeds nicotine addic-
tion and is a gateway to smoking. 
“Th e majority of youth who use 
e-cigarettes are already smokers. 
Th ere are some who are non-
smokers who are just experi-
menting with these products.” 
Siegel’s adversaries want to 
keep e-cigarettes from kids by 
hiding them from view com-
pletely. Siegel said just quit 
telling kids e-cigarettes are 
sexy and tell them what they 
really are. 
“You don’t see kids using nico-
tine patches and nicotine gum. 
Th at’s because they know that 
these are for smoking cessation. 
And that’s not a cool thing.”
—Sonya Collins
»
Helping doctors help 
themselves
Rows upon rows of manila 
fi le folders sit like soldiers on 
the credenza behind the desk 
of DeWitt “Bud” C. Baldwin 
Jr., M.D. ’49, where they have 
a bird’s-eye view of Chicago’s 
urban landscape and Lake 
Michigan. Th eir contents fuel 
the research that the 
93-year-old Baldwin conducts 
as a scholar in residence at 
the Accreditation Council for 
Graduate Medical Education 
(ACGME). Every day and often on 
weekends too, he reads, thinks, 
and writes in his 24th-fl oor 
offi  ce, often about job burnout. 
Not for his personal well-being, 
but for the growing number of 
trainees pushed to the brink by 
their chosen profession.
Ironically, doctors—who are 
drawn to helping others—suffer 
high rates of depression, sub-
stance abuse, divorce, and sui-
cide. Some 40 percent of medical 
residents report feelings of 
depression. As many as a dozen 
take their own lives every year, 
said Baldwin.
“Medicine today has become 
too complex for the still-rigid way 
we train physicians, leading to 
an intense, nonsupportive learn-
ing environment,” said Baldwin, 
who joined the American Medical 
Association in the mid-1980s 
to head the Offi  ce of Education 
Research. Th ere he launched 
pioneering studies that revealed 
disturbing fi ndings: Medical 
students and residents routinely 
endured a great deal of mental 
and physical abuse. “Years ago 
I said, ‘It’s not just the hours [resi-
dents work] but what goes on in 
those hours that matter.’ ”
Hired by the ACGME in 
2002, Baldwin focuses on bet-
ter understanding the resi-
dent experience. His research 
helps to develop strategies and 
guidelines that allow young 
physicians to heal themselves 
A grant helps a new 
American pursue a 
career in neuroscience.
Looking to her clerkship 
years, a med student 
learns about New Haven
Full stories and event 
photo galleries, as well 
as other online-only 
content, can be found 





ago, they remain relevant 
to graduate medical educa-
tion. In early 2016, the ACGME 
will bestow the first DeWitt C. 
Baldwin Jr. award to an aca-
demic institution that demon-
strates a humanistic culture and 
fosters a respectful and sup-
portive environment for medi-
cal education.
“Bud has taken the tempera-
ture of the soul of American resi- 
dents in ways no one else has,” 
said Timothy P. Brigham, M.Div., 
Ph.D., chief of staff and senior 
vice president for education at 
the ACGME. “He has touched 
the lives of literally thousands 
of physicians and, by extension, 
thousands of patients who  
have benefited from the impact 
of his work.”
—Cheryl SooHoo
At 93, Bud Baldwin is still 
hard at work, research-
ing the experience of 
residency and looking  
for ways to help young 
doctors in training deal 
with depression, sub-
stance abuse, divorce, 
and suicide. “It’s not just  
the hours that resi- 
dents work, but what 
goes into those hours 
that matters.”
or at least let others help them. 
To that end, Baldwin encour-
ages trainees to speak up via a 
variety of methods, including 
anonymous surveys to measure 
satisfaction and define the best 
learning methods.
“Bud has provided a venue for 
the voice of residents,” said Nick 
Yaghmour, M.P.P., a research 
analyst at the ACGME who 
assists with Baldwin’s studies. 
“He has brought the importance 
of physician communication and 
self-care into the discussion.”
A noted champion of human-
ism in medical education, 
Baldwin has long advocated 
reforming medical school cur- 
ricula. For him, such soft  
sciences as sociology and psy-
chology are as important to 
shaping future physicians as 
the hard sciences of biology and 
chemistry. He promoted the 
once-radical notion that bud-
ding practitioners must learn 
to appreciate that many factors 
influence health, from socioeco-
nomic status and cultural differ-
ences to gender and race.  
A maverick throughout his more 
than 60-year career, Baldwin 
practiced what he preached at 
four traditional and two new 
medical schools he helped to 
establish in Connecticut and 
Nevada. One of the founders  
of the Association for the 
Behavioral Sciences and Medical 
Education, he received the orga-
nization’s lifetime achievement 
award in 2007.
This physician educator 
didn’t stop at enhancing the 
development of well-rounded 
compassionate doctors. He also 
introduced the concept of inter-
professional teamwork: teaching 
physicians and other health pro-
viders to care for patients with 
a collaborative team approach, 
for which he has received two 
honorary doctorates. “I learned 
to think health instead of dis-
ease,” said Baldwin, who applied 
this model at the University of 
Washington in Seattle in the 
1950s. “When it comes to dis-
ease, doctors are the experts. 
When it comes to health, doc-
tors don’t know much. It’s the 
nurses, social workers, nutri-
tionists, dentists, and occupa-
tional therapists who help make 
people healthy.” His tenure in 
the Northwest also proved per-
sonally satisfying, as he met his 
wife, Michele. A French native, 
she was studying in the United 
States on a Fulbright scholarship. 
The couple has two daughters 
and four grandchildren.
Baldwin credits much of his 
passion for education to his par-
ents, who believed in experiential, 
small-group, and problem-based 
learning. They were educational 
missionaries in Burma (now 
Myanmar), where Baldwin lived 
until age 10. When they returned 
to the United States in 1933, he 
said, “They came back with the 
belief that ‘We have as much to 
learn as we have to teach’ and 
were promptly fired by their mis-
sion board.”
While Baldwin’s ideas for 
educational reform for physi-
















She has co-authored nine peer-
reviewed research articles and 
recently won a $5,000 medical 
student leadership award from 
Women In Medicine (WIM), a 
national organization that pro-
vides medical education and 
networking opportunities for 
lesbian, gay, bisexual, trans-
gender, and queer (LGBTQ) 
female physicians. In November 
2015, she earned a Best Poster 
Presentation award in Public 
Health at the American Medical 
Association interim meeting. 
Sitkin was subsequently elected 
to the board of WIM. “Nix has 
brought energy and clarity to 
LGBTQ issues, especially as 
they affect the education, prac-
tice, and professional experi-
ence of medical students and 
physicians. She has a voice 
in national discussions,” said 
Forrester A. Lee, M.D. ’79, 
HS ’83, associate dean for mul-
ticultural affairs and professor 
of medicine (cardiology). Sitkin 
recently sat down with Yale 
Medicine to talk about her work 
on LGBTQ issues.
How are you involved  
with LGBTQ issues at  
the School of Medicine?  
Last year I was president of 
the student group, OutPatient, 
previously the Gay Straight 
Medical Student Alliance. One 
of our first orders of busi-
ness was to change the name, 
since it wasn’t inclusive of 
the wonderful diversity of 
identities and experiences of 
LGBTQI+ folks. The “I” stands 
for intersex, an identity term 
sometimes used by people 
who biologically don’t fall into 
the male-female sex binary. 
The plus sign is meant to 
include whatever identities 
or experiences people may 
have. Additionally, last year I 
approached Dean Schwartz 
[Michael L. Schwartz, Ph.D., 
associate professor of neuro-
science and associate dean 
for curriculum] with a pre-
sentation on LGBTQI health 
disparities, physicians’ power 
to perpetuate or mitigate 
those disparities, and the 
first LGBTQI physician train-
ing guidelines, issued by the 
AAMC in 2014. That conversa-
tion blossomed into an ongoing 
collaborative effort between 
faculty, staff, and students to 
incorporate new and enhance 
existing LGBTQI health con-
tent in the curriculum.
What might a sample of 
medical education on 
LGBTQ health look like?  
Our idea is to provide train-
ing like a spiral staircase. 
   Why Nicole Sitkin adds  
  a plus sign to LGBTQI+
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W H E N S E C ON D-Y E A R M E DIC A L S T U DE N T Nicole Sitkin 
speaks, her words flow quickly, her sentences packed 
with information, just as her professional life brims 
with accomplishments. In June 2013, the University 
of California, Davis, awarded Sitkin the University 
Medal, given to the top graduating senior who excels in 
academics, community service, and promise of future 
scholarship. In September 2014, Sitkin was appointed 
to the Learning Environment Sub-Committee of the 
Association of American Medical Colleges (AAMC) 
Advisory Committee on Sexual Orientation, Gender 
Identity, and Sex Development. 
{To nominate a subject for Q&A, contactYale Medicine, 1 Church Street, Suite 300, New Haven, CT 06510 or email ymm@yale.edu





You start at the bottom with 
the facts. For example, what 
do the terms LGBTQ, inter-
sex, and cisgender mean? 
How does sex differ from 
gender, which differs from 
sexual orientation? As stu-
dents progress, they acquire 
communication tools, such 
as by practicing inclusive 
interviewing with standard-
ized patients. During clerk-
ships, students then have the 
opportunity to reflect on real 
patient care experiences and 
to hone and implement their 
knowledge and communica-
tion skills.
In your experience, do 
peers feel comfortable 
being “out” on medical 
school campuses? There 
has been limited institu-
tional support for sexual and 
gender minority individuals 
at medical schools histori-
cally. Fortunately, the cul-
ture of medical education 
is shifting in parallel with 
society generally, to greater 
respect and recognition of 
the lives and identities of 
LGBTQI folks. That being 
said, everyone’s experience 
is different. Some folks may 
never want to be “out” in a 
professional context, while 
it may be very important to 
others to have their identity 
recognized. Institutional 
culture and visible sup-
port systems also deeply 
dean for student affairs] and 
Dean Lee is what we can do 
to institutionalize LGBTQI 
programming in terms of 
formal curriculum, support 
services, and educational 
opportunities for  
the whole health campus.  
We are actively seeking 
to bring together people, 
LGBTQI and allies, and  
to identify resources to  
support this work. We  
welcome the involvement  
of any Yale community 
members interested in 
LGBTQI health.
affect whether students feel 
comfortable and safe being 
out. I know students who 
are uncertain about whether 
they can be out in their pro-
fessional lives. For people 
who are figuring it out or are 
coming out, it’s so impor-
tant to be able to connect. 
I’m out, I have a partner I’m 
crazy and open about, and 
I still benefit so much from 
interacting with supportive 
allies and LGBTQ role models 
and mentors at the School 
of Medicine. At Yale, we are 
bringing together faculty, 
staff, and other resources to 
provide more visible, acces-
sible support for students.
What is your partner, 
Mariko Zelin, doing now?  
Mariko is a gifted research 
scientist. She’s currently 
doing research at a start-up 
company while completing 
a master’s of science in bio-
technology at Northwestern 
University. She’ll be graduat-
ing in December and moving 
to New Haven. She’s excited 
to explore the opportunities 
in the biopharmaceutical 
industry out here.
What can people do  
to support the LGBTQI+  
community? One of the 
ideas I’ve talked about with 
Dean Angoff [Nancy R. 
Angoff, M.P.H. ’81, M.D. ’90, 
HS ’93, associate profes-
sor of medicine (general 
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  Winning  
the war on cancer
 By Cathy Shufro
Vincent T. DeVita Jr., M.D., 
HS ’66, had “zero interest in 
cancer” when he began a fel-
lowship at the National Cancer 
Institute (NCI) in 1963. But 
he decided that even cancer 
research sounded better than 
“getting shot at in Vietnam.” 
The Death of Cancer fol-
lows DeVita’s transformation 
from a reluctant researcher to 
a leader in a struggle that he 
says we’re winning. DeVita 
communicates that same 
optimism in the hefty subtitle 
of the book that he wrote with 
his daughter, science writer 
Elizabeth DeVita-Raeburn, 
M.P.H.: After Fifty Years on 
the Front Lines of Medicine, 
a Pioneering Oncologist 
Reveals Why the War on 
Cancer Is Winnable—and 
How We Can Get There. 
They wrote the book, says 
DeVita, because, “The people 
who have put over $100 billion 
into the war on cancer have 
the right to know what was 
done with it.”
 It’s a story that DeVita, 
now 80, has witnessed at 
NCI and on Capitol Hill, at 
Memorial Sloan Kettering 
Cancer Center in New York, 
and at Yale Cancer Center, 
which he directed for a decade. 
At NCI, part of the National 
Institutes of Health (NIH), he 
climbed the ranks to serve 
as director from 1980 to 1988. 
His daughter was there, too: 
“People talk about Army brats, 
and there was such a thing 
at NIH. I grew up around all 
the oncologists,” said DeVita-
Raeburn. “I thought all men 
carried beepers.” 
Her mantra was to make 
the book “relentlessly use-
ful.” It warns that when a 
doctor is willing to reduce a 
chemotherapy dose to mini-
mize horrible side effects, or 
schedules treatments based 
on convenience rather than 
the life cycles of cancer 
cells, that doctor might be 
knocking out a patient’s best 
chance of survival. It advises 
readers that no name-brand 
cancer center, including 
Yale’s, can offer optimal 
treatment for every type of 
cancer; different institutions 
do better with different can-
cers. It provides recommen-
dations, with the caveat that 
they’ll soon be outdated.
The book begins by 
describing how DeVita 
thought through which 
prostate cancer treatments 
to suggest to a family friend. 
It closes with the story of 
DeVita himself, who suffered 
“the double curse of being 
a doctor who gets a disease 
from his own field.” The book 
explains how he charted his 
own cancer treatment. (He 
says he’s doing fine.)
 The Death of Cancer 
illustrates how greed, turf 
wars, and myopia have often 
obscured the central goal of 
patient survival. Nonetheless, 
argues DeVita, “The war on 
cancer is being won, though 
the general tenor in the 
press is that it’s not.” That 
may be because reporters 
focus on short-term setbacks, 
not the big picture, says 
DeVita-Raeburn. 
Overall cancer mortality 
has dropped by 25 percent 
since the 1990s. Due to three 
paradigm shifts, beginning 
in the 1960s with the rec-
ognition that combination 
chemotherapies worked better 
than single drugs, DeVita and 
colleagues designed a four-
drug treatment that for the 
first time cured patients with 
advanced Hodgkin’s disease, 
for which he won a presti-
gious Lasker Award in 1972. 
At a time when most tumors 
were treated with surgeries 
and radiation, the treatment 
proved that chemotherapy 
could vanquish cells that 
escape tumors to enter the 
bloodstream or organs. The 
second shift was the advent 
of targeted therapies, which 
can turn cancer into a chronic 
rather than a fatal disease. 
The third shift derives from 
new approaches that use a 
patient’s own immune system 
to quell cancer. 
“The best is yet to come,” 
said DeVita. “I think you’re 
going to see some really star-
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LU NC H T I M E PA I N T I NG B E C OM E S A B R E A K F ROM T H E OF F IC E . Ni La and Roshni 
Srivastava, researchers in cardiovascular medicine, were among about 30 Yale workers, 
ranging from postdocs at the School of Medicine to IT techs to administrative assistants, 
who spent a lunch break painting in August. Being Well at Yale sponsors the painting 
class as a way to ease the stress of the workplace.
“We’re looking for a creative way to encourage employees to step away from the offi  ce for 
a little bit, recharge, and reset,” said Lisa Kimmel, manager of Being Well at Yale. Art Plus 
Studio on Chapel Street hosts the once-a-month painting sessions. Rachel Rasfeld, 
an instructor at the studio, guided the painters through the process. “It’s like art therapy. 
We do a painting together, but the point is to relax,” Rasfeld said.
—John Curtis
Not by the numbers
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{To view a video on  the lunchtime art class, visit yalemedicine.yale.edu/art
